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Abstract 
This work reports on the psychometric properties of a new measure designed to screen 
for distress in large populations of cancer patients. The Distress Thermometer (Holland et aI., 
2000) was tested in a group of 239 heterogeneously diagnosed cancer patients. It was found to 
be internally consistent (~ = 0.86) and to exhibit a reliable eight-factor solution. It displayed 
acceptable concurrent validity (2':::: 0.0001) when compared to the Rotterdam Symptom 
Checklist (deHaes et aI., 1994), the Functional Living Index Cancer (Schipper et aI., 1984) and 
the Brief Symptom Inventory (Derogatis, 1993). It was also found to be a sensitive measure of 
subsyndromal distress. 
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Introduction 
A cancer diagnosis often leads to an existential crises (Weisman & Worden, 1976-77). In the 
philosophical sense this crises may be replete with 0ppOliunities to acknowledge the mortal 
nature of human ~xistence and to construct a more authentic life (Bolmsjoe, 2000). In terms of 
psychological experience the distress that accompanies the crises adds to suffering associated 
with the disease (Baider & DeNour, 1977; Foley, 1999; Holland, 1997), to its morbidity (Fawsy, 
1994; Holland, Lloyd, 1979; McDaniel, Musselman, Porter, Reed & Nemeroff, 1995), and 
perhaps, to its mortality (Derogatis, Abeloff & Melisaratos, 1979; Faller, Bulzebruck, Drings & 
Lang, 1999; Fawsy, Morrison & Paffenbarger, 1981). 
Problem Statement and Purpose of the Study 
Problem. 
In 2001some 1,268,000 Americans received a new cancer diagnosis and 553,4000 died 
from the disease (American Cancer Society, 2001; ACS). A seminal study (Derogatis, et al., 
1983) finds that 47% of those with cancer diagnoses will experience distress sufficient to 
increase the disease's morbidity. Later studies estimate the prevalence of psychological 
morbidity in cancer populations to range from 48.2% (Chochinov, Wilson, Enns & Lander, 
1994) to 0% (Roberts, Rossetti, Cone & Cavanaugh, 1992) depending on the population studied 
and the criteria used. (See section entitled "Prevalence of Psychiatric Diagnoses in Cancer 
Populations" for further discussion.) The atmual cost associated with cancer's morbidity is 
estimated to be $180.2 billion (ACS). Untreated distress accrues cost both in terms of the loss 
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of the quality of cancer patients' lives and of their health care. The development of a pragmatic 
and sensitive way to diagnosis distress in the cancer population is the first step toward reducing 
untreated distress. It is a key initiative in the psycho-oncology community (Foley, 1999; 
Holland, 1997; Holland, Foley, Handzo, Levy & Loscalzo, 1999). The Distress Thermometer 
(DT) (Holland, et'lil., 2000; see Appendix A) is a linear analogue scale that is likely to help 
meet this initiative. The Distress Thermometer's reliability and validity as a measure of distress 
in cancer populations has not been established. 
Purpose. 
The purpose of this study was to describe some of the DT's (Holland et al., 2000) 
psychometric properties in a sample of cancer patients. The scale's internal consistency and 
factor structure was examined. Its performance was compared to three established measures of 
aspects of distress in cancer populations: the Rotterdam Symptom Inventory (RSI) (deHaes, van 
Knippenberg, & Neijt, 1990; see Appendix B), the Functional Living Index Cancer (FLIC) 
(Schipper, Clinch, McMurray & Levitt, 1984; see Appendix C), and the Brief Symptom 
Inventory (BSI) (Derogatis, 1993; Derogatis, Dellapietra, & Kilroy, 1992; see Appendix D). 
Problem Parameters 
Complex issues that impede the diagnosis of the full spectrum of distress in cancer 
popUlations have been widely discussed (Barg, Cooley, Pasacreta, Senay & McCorkle, 1994; 
Bieliauskas & Garron, 1982; Coyle, Layman-Goldstein, Passik, Fishman & Portenoy, 1996; 
Foley, 1999; Holland, 1997; McDaniel et al., 1995; O'Boyle & Waldron, 1997; Portenoy, 
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Thaler, Kornblith, McCarthy-Lepore, Friedlander-KIaI', Coyle et aI., 1994; Valente, Saunders & 
Zichi-Cohen, 1994). This discussion is summarized below. 
First, the literature indicates that routine psychosocial assessment in cancer populations 
does not occur. Cancer patients and their families often report that their psychosocial needs are 
not met. In the 80s tw6 surveys were commissioned by the Cancer Control Advisory Board of 
the Pennsylvania Department of Health (Houts et aI., 1988; Houts, Yasko, Kahn, Schelzel & 
Marconi, 1986). The goals of the surveys included descriptions of the umnet needs of cancer 
patients during the first year after diagnosis and in the terminal period. Results indicated that 
59% of cancer patients in PelIDsylvania have at least one unmet need in the year following 
diagnosis (Houts et aI., 1988; Houts et aI., 1986). The need for assistance with emotional issues 
that accompany the disease was the most frequently reported unmet need. In the terminal phase, 
72% of the surveyed patients identified unmet needs. The two most frequently cited were 
insufficient help with physical problems and lack of assistance to ameliorate emotional issues 
associated with the disease (Houts, et aI., 1988). Clinical reports (Holland, 1997) verify that 
patients consider provision of services that meet their emotional needs to be an important part of 
their care. Forty-four percent of the recipients of the results thought that lack of psychosocial 
assessment lead to neglect of the patients' emotional needs (Houts et aI., 1988). Cull, Steward 
and Altman (1995) conclude that many institutions have no policy requiring that cancer patients 
be screened for emotional issues. Adding to the challenge, neither psychological screening nor 
psychological services are among the criteria that an institution must meet to be designated a 
comprehensive cancer center for research purposes (McQuellon, Hurt, & DeChatelet, 1996). 
The second issue that hampers psychosocial assessment in cancer populations has been 
described as a lack of correlation between the physicians' perceptions and the patients' actual 
level of psychosocial functioning. An initial study of 23 cancer patients and their primary 
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physicians reported that physicians' estimations of the patients' emotional distress correlated 
poorly with the patients' self-reports (Derogatis, Abeloff & McBeth, 1976). Physicians tended 
to overestimate patients' levels of anxiety while underestimating their levels of depression. 
Later studies (Ford, Fallowfield & Lewis, 1994; Monahan, 1988; Sollner, Zingg-Schir, 
Rumpold, Mairinger & Fritsch, 1998) report similar results. Researchers also found that the 
proficiency of physicians' ratings varies among patients (Sollner et al.) and that some 
physicians are consistently more proficient than others in describing their patients' emotional 
states and quality oflife (Ford et al.). Even the best correlations between the physicians' 
estimation of emotional distress and the patients' self reports are moderate (Ford et al.; 
Stephens, Hopwood, Girling & Machin, 1997). In some cases a negative relationship between 
the physician's perceptions and the patient's report exists (Ford et al.; Sollner et al.). This 
research points to the conclusions that many physicians misperceive patients' emotional state 
and often underestimate the amount of distress patients are experiencing. For example, Holland 
(1997) claims that 51 % of the cancer patients at Memorial Sloan Kettering Hospital have 
symptoms that are congruent with a psychiatric diagnosis, especially anxiety or depression, and 
that most psychiatric symptoms go unrecognized. 
In a review of the literature, Valente, Saunders and Zichi -Cohen (1994) suggest that 
myths account for some of the disparity between patients' estimates of emotional distress and 
those of their physicians. These myths include the following topics: (a) a consensus among 
health care providers that affective distress and perhaps even suicide contemplation are 
understandable and expected reactions to a cancer diagnosis and therefore do not require 
treatment; (b) professionals' proclivity to worry that responding to affective problems is too 
time consuming; and (c) common beliefs that cancer patients' affective symptoms are really 
lack of motivation, laziness and/or noncompliance. 
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After studying the psychiatric morbidity in a sample of 117 cancer patients receiving bad 
news, Ford, Lewis & Fallowfield (1995) agreed that poor patterns of identification of cancer 
patients in need of psychological follow-up are related to the reluctance of both patients and 
physicians to discuss psychological issues. They also suggested that the belief that distress and, 
thus distress assessment, should be confined to certain points on the disease trajectory 
constituted an additional widely held myth. For example, distress may be thought to be 
problematic exclusively at times when bad news is received or when the disease leads to a 
terminal outcome. Despite this evidence, many physicians continue to hold the view that they 
are proficient at identifying distress (Fallowfield, Ratcliffe, Jenkins & Saul, 2001). 
Another issue that interferes with proper assessment is that distress often becomes 
problematic in cancer populations before its symptoms reach the threshold criteria for a 
psychiatric diagnosis (Holland et aI., 2000; Holmes, 1991). This presents a unique problem for 
psychosocial assessment in oncology because cutoff scores and instruments used to confirm a 
psychiatric diagnosis may not be sufficiently sensitive to detect distress in cancer populations. 
Reviews of the literature conclude that subclinical emotional distress is common in cancer 
populations and differs from major mood disorders not only in level of severity, but also in the 
breadth of symptoms described (Sollner, et aI., 1998; Tope, Ahles & Silberfarb, 1993). 
Although the symptoms often do not amount to a psychiatric diagnosis, they cause "significant 
islands oflife disruption" (Tope, p.1 02). Roberts, Rossetti, Cone and Cavanaugh's (1992) study 
of 32 cancer survivors demonstrates this sub-clinical disruption. Although 31 of the 32 subjects 
reported unmet needs for psychological services, 100% of the study subjects scored well below 
all criteria necessary for the diagnosis of emotional illness and all reported good quality-of- life 
scores. Therefore, the subjects were distressed by their own repOli but not emotionally ill. 
Rhodes, McDaniel, Homan, Johnson, & Madsen, (2000) compared a sample of 175 oncology 
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patients with 82 patients with other medical concerns that included elective surgery; acute 
conditions such as myocardial infarction or cholecystitis; or exacerbation in chronic conditions; 
such as diabetes mellitus or chronic obstructive pulmonary disease. This study did not try to 
establish psychiatric diagnoses, but the authors found that the cancer population reported 
significantly more distress than the medical-surgical population. Even a subclinical level of 
distress associated with cancer symptoms had a profound impact on the quality of life for 243 
cancer patients with heterogeneous diagnoses (Portenoy, et aI., 1994). Holland (1997) calls this 
level of distress "subsyndromal" and proposes that distress screening occur for all cancer 
patients so that appropriate interventions might be delivered. A complete psychiatric screening 
may follow distress screening, if indicated for individual patients. 
If an instrument were sensitive enough to diagnose subsyndromal distress, and 
administratively practical, then high-risk individuals might be identified and the unrealistic goal 
of treating all cancer patients as if they were at high risk for distress (Barg, et aI., 1994) 
modified. The issue of clinical practicality frames standards for a viable screening tool. Roth et 
al. (1998) call attention to the recent movement of cancer care from a primarily inpatient arena 
to outpatient practices. This resulted in fewer professional person-hours per patient and made 
the press for a rapid means of identifying distressed patients more important than in previous 
decades. 
A number of other barriers impede routine screening for distress in large cancer 
populations. In reviewing the literature, Sollner and colleagues (1998) concluded that although 
the clinical interview is the gold standard for establishing distress, it is too administratively 
demanding to use for routine screening. Some well-respected paper and pencil tools like the 
Minnesota Multiphasic Personality Inventory (Butcher, 2000) and the Symptom Checklist-90 
(Derogatis & Savitz, 1999) are self-administered. However, they are also burdensome because 
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of the costs associated with the purchase of the testing and scoring equipment for ongoing large 
populations and the personnel time required for scoring, interpretation and reporting (Derogatis, 
1993). Additionally, many cancer patients who fatigue easily find the exercise of completing 
lengthy self-reports unacceptable (Holland et aI., 2000). 
Holland's (1997) position paper summarizes some of the previously discussed hurdles to 
distress screening and evaluation in cancer populations. She draws on many years of psycho-
oncology experience to reach three conclusions. First, physician attitudes often interfere with 
effective screening for distress. Second, the continuum of problematic emotional experience in 
cancer differs from psychiatric diagnoses, and screening for psychiatric diagnoses often misses 
many emotional problems associated with cancer. Third, the administrative burden associated 
with some measures prevents their use for screening in large cancer populations in time 
constrained health care settings. 
Criteria for Distress Assessment in Medical Settings 
Given the interest in improving distress assessment, researchers have reviewed the 
literature (Finlay & Dunlop, 1994; Grant, Padilla, Ferrel & Rhiner, 1990) and convened a panel 
of experts (Barg, et aI., 1994) to define the requirements for a screening tool to be used in 
oncology settings. As a result, criteria against which to judge the utility of an instrument for 
measuring distress in oncology were constructed. The defined criteria listed below propose that 
the instrument should be: (a) specific for cancer (Barg; Finlay; Grant); (b) self-administered and 
easily interpretable by professional level staff without special training (Barg; Finlay; Grant); (c) 
amenable to re-test (Finlay); (d) sensitive enough to identify people at risk for psychosocial 
problems (Barg; Finlay, Grant); (e) short and should not contribute to response burden (Barg; 
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Finlay); (f) tied to a triage and referral system (Barg); and (g) designed to identify problems in 
multiple dimensions (Barg). 
Most available distress screening instruments fail to meet some of these criteria (See 
section entitled "Distress Screening Tools" for a review of screening instruments). The Distress 
~ '< ' 
Thermometer meets these criteria and may prove to be a viable initial screening tool in large 
cancer populations. Subsequent sections of this work define distress within the problem-coping 
framework, and review the current literature on the prevalence of and risk for distress in the 
general cancer population. The current methods of distress assessment in cancer populations 
are then reviewed and critiqued. The Distress Thermometer (National Comprehensive Cancer 
Network [NCCN], 2000) is then described. This description is followed by the results of a 
research project conducted to examine its reliability and validity in a sample of cancer patients. 
The final section discusses and draws conclusions from the study. 
Definitions of Distress 
Popular Definition. 
Distress is a natural concept with popular definitions. These definitions are: 
When used as a verb it means to cause sorrow, misery, or suffering; to 
make unhappy, anxious, etc.; pain; afflict; trouble. When used as a noun 
it means the state of being distressed; pain; grief; anxiety; suffering or 
anything that distresses; affliction or a state of danger or trouble; bad 
straits. It implies mental or physical strain imposed by pain, trouble, 
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worry or the like and usually suggests that the state can be relieved. 
(Webster's New World Dictionary of the English Language, 1968, p. 330) 
Conceptual Definitions. 
In the cancer literature the term "distress" is defined in at least three ways depending 
upon the framework within which it is conceptualized. In the first iteration, many authors refer 
to psychosocial distress or emotional distress as general terms for any psychiatric diagnosis or 
positive result in psychological testing in a cancer population (Akechi, et aI., 2000; Baider & 
DeNour, 1997; Bredart, et aI., 1999; Farber, Weinerman & Kuypers, 1983; Kugaya, Akechi, 
Okuyama, Okamura & Uchitomi, 1998; McQuellon et aI., 1998; Passik, Newman, Brennan & 
Tunkel, 1995; Sollner et aI., 1998). This psychiatrically based definition may correctly apply to 
a subset of the cancer population whose symptomatology meets guidelines for emotional illness. 
It also may result in incorrect clinical conclusions as the symptoms that lead to psychiatric 
diagnosis like fatigue, anorexia, irritability and disturbed cognitive processes also result from 
cancer pathology and! or treatment agents (Valente, Saunders & Zichi -Cohen, 1994). 
In the second conceptual framework either the term "distress" or the phrase 
"psychological distress" is used either to describe the emotional dimension of a 
multidimensional quality oflife construct that is applied to the cancer experience (O'Boyle & 
Waldron, 1997; Roberts et aI., 1992; Schag, Ganz & Heinrich, 1991; Schag & Heinrich, 1990; 
Schag, Heinrich & Aadland, 1990; Schag, Heinrich & Ganz, 1984; Zabora et aI., 1997) or to 
indicate lack of quality of life (Coyle et aI., 1996). From this perspective, distress is the 
opposite of well being (McQuellon et aI., 1996) and well being is one component of quality of 
life (Tope et aI., 1993). Emotional symptoms are one of a large number of varying determinants 
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of well being. The quantification of the symptoms of distress and the degree of impact on the 
total quality of life varies greatly among instruments used to measure quality of life in cancer 
patients (Grant et at., 1990). 
In the third framework, distress is a subjective, sometimes disabling symptom that 
occurs because of an inability to solve or cope with the problems associated with the experience 
of having cancer and with cancer treatments (Holland, 1997; Nezu, Nezu, Friedman, Faddis & 
Houts, 1998; Peruselli et at., 1993; Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-
IGar, Coyle, et at., 1994; Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, 
Kiyasu et at., 1994; Rhodes, McDaniel, Homan, 10hnson & Madsen, 2000; Roth et at., 1998). 
This third locus of interest is the most pragmatic from a clinical viewpoint. It enables clinicians 
to narrow attention to particular problems within a quality of life framework and accepts that no 
single phenomena are universally associated with distress. A phenomenon causes distress if, 
and only if, the client cannot cope with it. Therefore, distress is not a syndrome easily 
measured against external criteria (like the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, 1998; DSM-IV), but rather, is gauged by the client's subjective 
experience. 
NCCN Definition. 
The NCCN (1998) a consortium of 18 nationwide leading cancer centers, has met 
annually for the past six years. The members of the network agreed upon a problem-coping 
conceptualization with distress defined as an unpleasant reaction to problems in psychological, 
social, physical or spiritual domains associated with having cancer. Specifically, they define 
distress in cancer as: 
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An unpleasant emotional experience of a psychological (cognitive, behavioral, 
emotional), social, and/or spiritual nature that may interfere with the ability to cope 
effectively with cancer and its treatment. Distress extends along a continuum, ranging 
from common normal feelings of vulnerability, sadness, and fears to problems that can 
become disabling, such as depression, anxiety, panic, social isolation, and spiritual 
crisis. (NCCN, 2000, p. DIS-2) 
Advantages of the NCCN Definition. 
The committee chose the term "distress" to define the emotional reactions associated 
with cancer, as it is acceptable to both patients and health care providers in a medical setting for 
at least three reasons. It removes the stigma of psychiatric, psychosocial, and emotional 
references from the patient care equation. It is framed in terms of normal and excessive 
reactions and is less embarrassing than words describing a breach in mental health. Last, it can 
be defined by self-report (NCCN, 2000). Holland (1997) observes from her clinical perspective 
that anything related to the mental domain carries a stigma and words such as emotional, 
behavioral, psychological and psychiatric offend oncology patients, while the word distress 
implies normal to severe feelings expressed by people with cancer as they face personal and 
illness-related issues. 
Additionally, the NCCN (2000) definition of distress is congruent with a large body of 
literature (Coyle et ai., 1996; deHaes et ai., 1990; Hurny et ai., 1993; McCorkle & Young, 
1978; O'Boyle & Waldron, 1997; Peruselli, et ai., 1993; Rhodes et aI, 2000; Schag, et ai., 1991; 
Schag & Heinrich, 1990; Schipper et ai., 1984; Sollner et ai., 1998) in its multiaxial format, 
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trait-like rather than state-like concept of distress and choice of self-report as the measure of 
presence, intensity and cause of distress. 
important Concepts in the Definition of Distress. 
The multi axial focus for the definition of distress became important in cancer 
populations as chronicity increased and the boundaries among physical, emotional, social and 
functional issues' impact on the cancer experience blurred. Table 1 summarizes the dimensions 
that have often been associated with distress in cancer populations. Most universally, deficits in 
physical functioning, including somatic symptoms, problems with psychological and/or social 
function and practical issues are thought to be sources of distress. It is essential that a 
multiaxial assessment include all four dimensions. 
The experience of distress in cancer populations is partially related to the disease's 
exacerbations and remissions and to changes in its treatment and treatment response (Zabora et 
aI., 1997). It is also influenced by the client's pre-illness level of able functioning and emotional 
history (Massie & Holland, 1990). A percentage of cancer patients have problems with family 
dynamics, under-employment, are poor and may have legal problems (Holland et aI., 1998). 
The imposition of a cancer diagnosis changes the experiential pattern (Weisman & Worden, 
1976-77), it may increase distress related to new problems and sometimes decreases distress in 
other areas. This points to the need for a trait-like, as opposed to state-like definition of 
distress. The NCCN (2000) inclusion of the concept of a continuum of experience is congruent 
with the trait conceptualization. Cull, Stewart and Altman (1995) observe that most of the 
patients in their routine oncology practice present with transient distress. Other expelis reached 
similar conclusions. For example, Pruitt, Waligora-Serafin, McMahon and Davenport (1991) 
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found that distress in a general cancer population decreased when measured both at 3 and 6 
months after the initial diagnosis. Lloyd (1979) analyzed the literature and found that the stage 
at which an emotional response to cancer is considered morbid is arbitrar 
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Table 1 
Variables Associated With Distress in Cancer Populations 
Tool (Authors) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1. Structured Interview (Coyle et aI., 1996) X X X X X 
2. Rotterdam Symptom Checklist (deHaes et aI., 1990) X X X X 
3. Functional Living Index Cancer (Schipper et aI., 1984) X X X X 
4. Perceived Adjustment to Chronic Illness Scale (Hurny et ai., 1993) X X X X X X 
5. Review (O'Boyle & Waldron, 1997) X X X X X X X X X X X X 
6. Symptom Distress Scale Italian Version (Peruselli, et aI., 1993), X X 
American version (McCorkle & Young, 1978) 
7. Memorial Symptom Assessment Scale (Portenoy, Kornblith, X X X X X 
McCarthy-Lepore, Friedlander-Klar, Coyle et aI., 1994; Portenoy, 
Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et ai., 1994) 
8. Adapted Symptom Distress ScaIe-2 (Rhodes et aI, 2000) X 
9. Distress Thermometer (Roth et aI., 1998) X X X X X X 
10. Cancer Rehabilitation Evaluation System and Cancer Rehabilitation X X X X X 
System- Short Form (Schag et aI., 1991; Schag & Heinrich, 1990) 
--
Tool (Authors) 
11. Hospital Questionnaire (Sollner et ai., 1998) 
-----
1 = Physical FunctlOnmg 
2= Psychological Functioning 
3= Social functioning 
4.=Financial and Material Well-being 
5= Overall discomfort 
6=Treatmetn Toxicity 
7=Body Image 
8=Informational Functioning 
9=Functional Status 
1 2 3 
X X X 
10= Sexual FunctlOnmg 
11= Somatic Symptoms 
4 5 
X 
12= Occupational Functioning 
13=Recreational Functioning 
14=Satisfaction with Treatment 
15=Health Status 
16=Future Prospects 
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6 7 8 9 10 11 12 13 14 15 16 
X X 
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O'Boyle and Waldron's (1997) conceptual analysis of quality of life in cancer 
populations finds that the impact of a particular problem on an individual patient's subjective 
experience of distress cannot be predicted. This trait-like definition of distress does not 
preclude the interaction between more stable personality variables and distress in the cancer 
experience. For example, researchers (Evans, Baldwin & Garth, 1974) find that individuals 
with mental illness are five times more likely to develop cancer than the normal population. 
Although not researched, it is reasonable to conclude that in this sub-population, the distress 
level may remain elevated throughout the course of the disease. 
Last, the NCCN definition accepts the consensus that distress is a subjective experience 
and only the patient can estimate the level of distress and communicate this level by self-report. 
Peruselli and colleagues (1993) and others (Holmes, 1991; Monahan, 1988) agree that distress 
refers to the amount of discomfort caused by a specific symptom as perceived by the patient. 
Holmes (1991) defines distress in cancer as the degree of discomfort from a specific symptom 
as perceived by the patient. Rhodes and colleagues (2000) explain that in order for distress to 
exist, the individual must be aware of the tension created by the problem and the degree of 
mental anguish associated with it. Although self-report may be subject to faking good or faking 
bad, and information that may be probed on interview missed, it is the only window to the 
patient's subjective experience (Derogatis, 1993). Further, self-report avoids the expense and 
administrative burden associated with interview (Derogatis; Finlay & Dunlop, 1994) and can be 
administered by paraprofessional staff (Derogatis). The self-report is also highly amenable to 
actuarial methods of scoring and interpretation (Meehl & Dalstrom, 1960) and is easily 
transportable (Derogatis). It is used by a large number of researchers to measure distress (Barg 
et aI., 1994; Ganz et aI., 1993; POlienoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, 
Coyle et aI., 1994). 
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The Distress Thermometer was developed to measure distress as defined by the NCCN 
(2000). In subsequent sections, the NCCN definition of distress will be used. In contrast, the 
terms "emotional illness", "psychiatric diagnosis" or "mental illness" are used to refer to 
conditions that meet DSM-IV (American Psychiatric Association; APA, 1994) diagnostic 
criteria. 
Additional Definitions 
Cancer. 
Anyone of more than 200 diseases involving disorganized abnormal cells that do not 
abide by the ordinary complex regulation that governs cellular reproduction, survival and death. 
These cells are not restricted to an anatomical location as are normal cells, nor do they reach a 
specified size and stop growing as normal tissues does. They cause symptoms by interfering 
with normal cellular and tissue functioning (Holland et aI., 1998) 
Quality of life. 
Quality oflife is an individual's subjective sense of well being derived from his or her 
current experience of life (Tope et aI., 1993). It is either general, referring to education, 
aesthetic experience and socioeconomic status, or health related and illness specific (O'Boyle & 
Waldron, 1997). 
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Functional status. 
Ability to independently accomplish activities that could be accomplished by the 
majority of healthy adults in any given culture (Schipper et aI., 1984). 
Coping. 
Ability to change either the internal (thoughts, feelings) or external environment 
(behaviors, relationships, tangible environmental factors) so in order to produce eustress 
(Lazarus, 1995). 
Theoretical Background 
The multiaxial focus and tension between physical or environmental presses and 
emotional symptoms that characterize the proposed understanding of distress are based on the 
neobehavioral, mulitmodal work of Lazarus (1995) and Lazarus and Folkman (1989). 
Arnold Lazarus (1995) proposes that our personalities stem from interplay among our 
genetic endowment, our physical environment and our social learning history. He does not 
accept the basic social learning triad of classical conditioning, operant conditioning and 
observational learning as explanatory for behavior changes. Instead he proposes that people 
respond to their perceived environment including their personal use of language, expectancies, 
selective attention, goals, attitudes, attributions and beliefs to produce behavior. If Lazarus is 
correct, then the experience of cancer becomes an attribute of both the internal and external 
environments, and the cognitive and emotional processes associated with it partially determine 
the cancer patient's behaviors. 
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Lazarus (1995) believes that in the course of being exposed to various situations people 
may acquire conflicting information, faulty cognitions and needless defenses. Emotional 
problems arise when individuals lack the necessary information and essential coping processes 
to handle situational demands. 
Folkman's (1984) extension of Lazarus's theory to health stressors began when she 
analyzed the role of personal stress and coping processes with health problems within the 
multimodal framework. Folkman applied a multimodal theoretical formulation of stress and 
coping to demonstrate the complexities of the perception of control over health events. She 
examined how the belief that one has control over health-related situations may increase threat, 
the relationship between control and coping, and the pathways through which control affects the 
adaptation to stressful encounters. 
Folkman also worked with Richard Lazarus and his associates (Folkman, Lazarus, 
Gruen & DeLongis, 1986) to examine the relationships among personality factors (mastery and 
trust), primary appraisal (the stakes an individual holds in a stressful situation), and secondary 
appraisal (the options for coping on the situation) in eight forms of problem- or 
emotion-focused coping, and physical health status and psychological symptoms. They found 
that the cognitive and behavioral coping strategies used across stressful situations were highly 
variable while the emotional forms of coping were more stable across situations. The 
personality factors, primary appraisal and coping variables accounted for a large amount of the 
variation in psychiatric symptoms, but were not related to physical health status. This suggests 
that distress levels may change as a function of personality, primary appraisal and coping 
strategies. 
In 1988, Folkman and Lazarus challenged the traditional assumption held by many 
health care providers that coping affects emotion. They proposed instead that the individual's 
emotional state influences coping choices. In testing this hypothesis in a sample of 75 married 
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couples, they discovered that some forms of coping are associated with increased positive 
emotions while other forms of coping are associated with increased negative emotions. This 
finding suggests that coping choices and emotion are interactive. With respect to distress, this 
tenant suggests that distress both influences and is influenced by coping choices. 
Later in the same year, the investigators (Lazarus & Folkman, 1989; Folkman & 
Lazarus, 1990) argued that coping mediates emotion in a process that involves at least three 
mechanisms: a) cognitive activity that directs attention; b) alteration and interpretation of the 
subjective meaning of an encounter or situation; and c) actions that alter the person-environment 
relationship. In this study, coping was found to mediate emotional responses in a sample of75 
married couples. Authors concluded that emotions and coping processes change as the subject's 
perceptions of and reactions to specific situations change. In accordance, it is likely that distress 
in cancer populations changes in specific situations and is inversely related to coping 
effectiveness. 
Of interest to the discussion, the same theoreticians also proposed and demonstrated that 
central hassles or ongoing themes and problems in an individual's life have a greater ability to 
define needs and to reveal deficits in coping skills than non-central issues (Gruen, Folkman & 
Lazarus, 1988). Psychological symptoms were found to be more highly associated with central 
hassles than non-central issues. A diagnosis of cancer might be a central issue for some people. 
In such cases, the diagnosis is likely to be associated with psychological symptoms or distress. 
The central issue theory is congruent with the conceptualization of distress as an 
emotional symptom related to a failure in coping strategies for situation specific problems in the 
central hassle of a cancer diagnosis. Distress, worsened by coping failure, may further impede 
effective coping (Gruen, Folkman & Lazarus, 1988; Nezu et aI., 1998). Consequently, distress 
measurement offers a vehicle for discrimination between cancer patients with adequate coping 
and euphoric emotional responses and those with poor coping and disphoric emotional 
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responses. When distressed patients are identified, interventions that prevent further emotional 
decompensation can be appropriately directed. 
Review of the Literature and Related Research 
Scope of the Review. 
The contextual understanding of relationships among emotional issues in general and the 
'cancer experience spans the literature of Western civilization (Hollandet al., 1998). The 
literature that informs our understanding about the concept of distress and its measurement in 
cancer populations by comparison is in its infancy. Since distress and psychiatric symptoms are 
related on a continuum, the most relevant clinical literature concerns the prevalence of 
emotional illness in cancer populations, the prevalence of distress in cancer populations and the 
risk profile for distress in cancer populations. Directly related research focuses on the efforts to 
develop instruments to screen for distress in cancer cohorts. The bodies of literature that 
address the prevalence of psychiatric symptoms and distress in cancer populations and the risk 
factors for distress in cancer popUlations are reviewed in this section. 
Limitations of the Review. 
Although conceptually interesting, three large areas of tangentially related to the concept 
of distress in the literature are excluded from the review. The following topics are excluded: 
(a) The broad body of literature that discusses or demonstrates links among distress/emotional 
factors and the incidence, progression and survival time associated with cancer (Le., Bieliaukas 
& Garon, 1982; Derogatis et al., 1979; Faller et al., 1999); 
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(b) The literature that addresses the relationships among distress and immune function in cancer 
populations (i.e., Fawsy, 1994; Fawsy, et aI., 1990); (c) The relationship between premorbid 
personality and levels of emotional illness/distress and the development of cancer (i.e., Dattore, 
Shontz, & Coyne, 1980; Shekelle, et aI., 1981; Todarello et aI., 1994). 
Prevalence of Psychiatric Diagnosis in Cancer Populations. 
Estimations of the prevalence of emotional illness or the percentage of cancer patients 
that meet the criteria for a psychiatric disorder range from no disorder (Roberts, Rossetti, Cone, 
& Cavanaugh, 1992) to 50% (Craig & Abeloff, 1974). The most frequently cited investigation 
(Derogatis, et aI., 1983) of 215 patients newly diagnosed with a variety of cancers found that 
47% of patients met criteria for a psychiatric disorder. Of this 47%, 44% met Axis I (APA, 
1994) diagnostic criteria and 12% met Axis II (AP A) criteria. Adjustment disorders had a 
prevalence rate of 32%, major affective disorders 6%, organic disorders 4%, personality 
disorders 3% and anxiety disorders 2%. Table 2 summarizes the studies that investigated 
emotional illness patterns in cancer populations. For each identified study, it presents the size 
of the sample, description of the population, the intervening variables controlled for, the method 
of measurement, and results. The disparity in the results can be explained by the complexity of 
and difficulty in controlling for the intervening variables: history, ethnic variability, variation in 
sampling methods and sizes, lack of control groups, and the divergent methods of measurement. 
There are at least three pervasive methodological problems with these studies. First, the 
prevalence of emotional illness in cancer patients has been demonstrated to be related to a large 
number of intervening variables. These include the type and location of the cancer (Holland, 
1998; Lloyd, 1974), the stage of the disease (Akechi et aI., 2000; Tope et aI., 1993), physical 
symptoms (Bredart et aI., 1999; Weisman & Worden, 1976-77), attitudinal factors (Lloyd; 
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Weisman & Worder), social status (Cull et aI., 1995; Lloyd; Weisman), functional status 
(Bredart) 
et aI., 1999; Derogatis et aI., 1983), psychiatric history (Cull; Evans, Baldwin, & Garth, 1974; 
Lloyd; Weisman & Worden), age (Bredart et aI.), substance abuse history (Weisman & 
Worden), gender (Btedart et al.), intrusive thoughts (Baider & Denour, 1997), degree of self-
monitoring (Schwartz, Lerman, Miller, Daly & Masney, 1995), and type of treatment (Holmes, 
1991; Lloyd). The nature of the relationship between the variables and distress is discussed in 
greater detail below. None of the reviewed studies controls for all the potential intervening 
variables. Such an investigation would require an enormous sample and a large test burden that 
may be unacceptable in a population that fatigues easily. 
Second, examination of Table 2 reveals that most conclusions about the prevalence of 
emotional illness in cancer populations are drawn from convenience with no attempt to draw a 
random sample (Bieliaukas & Garron, 1982; Craig & Abeloff, 1974; Farber, Weinerman & 
Kupers, 1983; Kugaya et aI., 1998). Randomization is essential to control for the large number 
of possible intervening variables. For example, in Farber and colleagues' study of216 
histologically confirmed mixed cancer patients, the sequential sampling technique did not 
control for history of emotional illness, stage of disease, length of time since diagnosis, or 
gender. The result that 34.4% of sample patients are distressed according to SCL-90 (Derogatis 
& Melisaratos, 1983) might be attributed to the patients' prior emotional status, to the recent 
nature of diagnosis, or to the fact that this data was collected on the patient's first visit to a 
cancer center or perhaps to gender or age. It is difficult to have confidence in the accuracy of 
the reported results. 
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Table 2 
Prevalence of Affective Disorders in Cancer Populations 
Study n Method/Instrument Subjects Variables Controlled 
.' 
Incidence 
Akechi et aI., 2000 885 Retrospective chart Japanese cancer patients 12.9% ofthe sample 
review for DSM-IV with mixed diagnoses met criteria for MDD. 
(1999) criteria for Major referred to the 535% of the depressed 
Depressive Disorder psychiatry division of population had suicidal 
(MDD) the national cancer ideation 
hospitaL 
Bredart et aI., 1999 220 Hospital Anxiety and Italian patients with Gender 34% exceeded the 
Depression Scale mixed diagnoses at the Age cutoff for psychiatric 
(HADS; Zigmond & European Institute of symptoms 
Snaith, 1983) Oncology in Milan 16% met criteria for 
anxiety or MDD 
Holland and Mastrovito, 1980 62 Clinical Interview Level of depression: at 42.0% were depressed 
Beck Depression least moderate on interview 
Inventory (BDI, Beck, 36.0% had BDI scores 
- ------- ----
------ .... -
-
- -- --
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Study n Method/Instrument Subjects Variables Controlled Incidence 
I 
I 
• 
Steer, & Garbin, 1988) of14 or more ! 
Chochinov et a!., 1994 l30 Schedule for Affective Terminally ill ' 9.2 % major 
Disorders (SADS; outpatients with mixed depression 
Endicott & Spitzer, diagnoses 13.0 % moderate 
1978) symptoms 
26.1 % minor symptoms 
Craig & Abeloff, 1974 30 SCL-90 (Derogatis & Inpatients at a Baltimore Mean scores were 
Melisaratos, 1983). hospital with mixed equivalent to the normal 
cancer diagnoses population. 
52% had depression 
indexes between T=50 
and T=60 
43% elevated 
somatization scores 
Dean, 1987 113 Present State Breast Cancer patients Gender 9.7% major depression 
------------
~-
---------
Validation Distress Thermometer 26 
Study n Method/Instrument Subjects Variables Controlled Incidence 
Examination (Dean, 17.7% minor depression 
1987) 
'-:-
Derogatis et ai., 1983 215 Clinical Interview Oncology inpatients at 47% had psychiatric 
SCL-90 (Derogatis & three collaborating diagnoses 
Melisaratos, 1983). cancer centers 68% adjustment 
Raskin Depression disorder 
Scale (RDS; 13% affective disorders 
Schulterbrandt, Raskin 4% organic disorders 
& Reatig, 1974). 3 % personality 
The Global Adjustment disorders 
to Illness Scale (GAl; 2% anxiety disorders 
Morrow et ai., 1981) 
Kamofsky Performance 
Scale (KPS; Nickelson 
et ai., 1976) 
Evans et aI., 1986 83 Clinical Interview Gynecological oncology 16.9% Adjustment 
patients Disorder with 
- ---- ----- --
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Study n Method/Instrument Subjects Variables Controlled Incidence 
Depressed Mood 
22.9% Major 
Depressive Episode 
Farber, Weinerman & Kuypers, 1985 216 SCL-90 (Derogatis & Canadian outpatients 34.4% had one scale in 
Melisaratos, 1983). with mixed confirmed addition to somatization 
malignancies elevated. 
22.4% had two scale 
elevations. 
Depression, OCD and 
Anxiety were the most 
frequently elevated 
scales 
Ford, Lewis & Fallowfield, 1995 117 General Hospital Cancer patients Course of the illness 30% of sample had 
Questionnaire-30 surveyed right after Gender psychiatric symptoms at 
(GHQ-30; Goldberg, hearing bad news Age time of news, 26% at 
1992) follow-up and 10% at 6 
HADS (Zigmond & months . 
. ----------- -
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Study n Method/Instrument Subjects Variables Controlled Incidence 
Snaith, 1983) 
Kathol, Mutgi, Williams, Clamon & Noyes, 152 Structured Interview Oncology outpatients ?5%-38%, dependent 
1990 with mixed diagnoses on the criteria 
employed. 
Morton et aI., 1984 48 Geriatric Mental State Geriatric Age 39.6% depressed 
Schedule (GMSS; buccopharyngeal 
Copeland et aI., 1976) carcinoma patients 
Plumb & Holland, 1977 80 Semi Structured Mixed diagnosis 45.0% at least moderate 
Interview (CAPPS; inpatients depression 
Endicott & Spitzer, 
1972) 
Roberts et aI." 1992 32 SCL-90 (Derogatis & Gynecological oncology Time since diagnosis 100% SCL-90 scores 
Melisaratos, 1983). survivors, no active within normal limits 
treatment 
Roth et aI, 1998 97 HADS (Zigmond & Gender 13% had psychiatric 
Snaith, 1983) symptoms, of the 13%: 
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Study n Method/Instrument Subjects Variables Controlled Incidence 
32.6% were anxious, 
and 15.2% were 
depressed 
Weddingtom. Segraves & Simon, 1986 33 SADS (Endicott & Patients post amputation 24.2 % major 
Spitzer, 1978) with sarcoma depression 
15.2 % minor 
depression 
----
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Third, the choice of measurement tools often reveals a general bias for short tools 
(Costantini et aI., 1999; Farber, Weinerman & Kuypers, 1983; Ford et aI., 1995) developed in 
hospital populations but not in cancer populations. Unfortunately, the overlap in symptoms, 
etiology of cancer and its treatments, and the DSM-IV (1994) criteria for affective disorders 
may lead to under diagnosis of affective problems in cancer populations (Lynch, 1995; Massie 
& Holland, 1990) if tools do not allow for this overlap. A review of competing etiologies for 
depressive symptomatology (Valente et aI, 1994) suggests that the physiologic symptoms of 
depression, including: appetite change, weight change, insomnia, avolition and fatigue, can 
often be accounted for by neurologic, metabolic, nutritional, pharmocologic or endocrine 
changes resulting from cancer or its treatments. The same cancer pathology and treatments 
often contribute to the development or exacerbation of affective disorders. One solution to this 
problem (O'Boyle & Waldron, 1997; Whitlock & Siskind, 1979) is to isolate symptoms typical 
of the affective disorder in the cancer population. For example; hopelessness, anhedonia, lack 
of future focus, and suicidal ideation, rather than the classic somatic symptoms (fatigue, 
anorexia and insomnia), might be the criteria for a depression diagnosis in this population. 
Another solution involves a change in the diagnostic locus from taxonomy to experiential 
criteria and from a threshold model to a continuum model (Holland, 1997). 
The Prevalence of Distress in Cancer Populations. 
Very little is known about the prevalence of distress in cancer populations. Perhaps little 
can be known as distress varies greatly among individuals and is situational. The existing 
estimates of distress prevalence often accompany reports of the psychometric properties of 
instruments designed to measure distress, or an aspect of distress, in cancer populations. For 
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example, using the Memorial Symptom Inventory (Portenoy, Thaler, Kornblith, McCarthy-
Lepore, Friedlander-Klar, Kiyasu et aI., 1994) in a sample of 243 cancer patients, researchers 
found that 60% of patients exceeded the cut -off score diagnostic of distress. Other researchers 
using different instruments found the prevalence of distress in heterogeneous cancer populations 
to be 54% (Pruitt et aI., 1991) and 72% (Holmes, 1991). Zabora and colleagues (1997) found 
that the prevalence of distress in cancer outpatients was 38%, while in terminal patients it was 
68%. Only one study used the Distress Thermometer (Roth et aI., 1998). In polling a sample 
of 97 prostate cancer patients, they reported that 28.6% of the sample indorsed distress scores 
exceeding the threshold for moderate symptoms. 
A few studies also report the number of symptoms that contribute to the patient's 
perception of distress. Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-KIaI', 
Kiyasu and colleagues (1994) found mean number of symptoms contributing to the reported 
distress to be 11. However, using the Symptom Checklist (Rhodes et aI., 2000) in 100 cancer 
patients, great variability of the number of symptoms contributing to distress was reported. The 
mean number of symptoms of28.7 +/- 13.4. 
It appears one-third to almost two-thirds of cancer patients can be expected to 
experience distress, that this experience is highly variable, and that the symptoms related to 
distress also exhibit a wide range of variability. However, studies in large cohorts of cancer 
patients aimed at analyzing the prevalence of distress are not reported in the literature. Increased 
clarity in the estimates of prevalence of distress in cancer popUlations awaits the completion of 
such research. 
Factors Related to Psychiatric Symptoms/Distress in Cancer Populations. 
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The risks of both psychiatric symptoms and distress are related to psychosocial and 
demographic factors and to ineffective coping (Nezu et aI., 1998). The research on the risk 
factors focuses on attributes of the highly distressed cancer population that differentiate it from 
the less distressed population (Akechi et aI., 2000; Baider & DeNour, 1997; Bredart et aI., 1999; 
Craig & Abeloff, 1974; Ganz et aI., 1993; Holmes, 1991; Passik et aI., 1995; Portenoy, Thaler, 
Kornblith, McCarthy-Lepore, Friedlander-Kjlar, Coyle et aI., 1994; Roth et aI., 1998; Zabora et 
aI., 1997). In contrast, the coping research focuses on divergent styles of perceiving the world 
and on problem-solving styles that differentiate more symptomatic from less symptomatic 
cancer populations (Behen & Rodrique, 1994; Burgess, Morris & Pettingale, 1988; Morrison, 
Hislop, Mears & Kan, 1991; Nezu et aI., 1998; Taylor, Helgeson, Reed & Skokan, 1991). 
The factors associated with psychiatric diagnosis and those associated with distress in 
cancer populations may not be orthogonally related. In fact, cancer patients with symptoms that 
meet diagnostic criteria for emotional illnesses would be expected to have more trouble coping 
and solving problems associated with the disease (Nezu et aI., 1998). However, there is no 
reason to believe that all factors that increase the risk for emotional illness in cancer populations 
also automatically increase susceptibility to distress. Rather, Nezu and colleagues suggested 
that an interactional model better accounts for patterns of cancer distress. In nonlinear 
interactions, cancer-related problems increase risk of distress and psychosocial factors increase 
or protect against this risk. For example, in one investigation of how social support influences 
distress in the breast cancer population, Bloom and Speigel (1984) found a positive relationship 
between social support from the patients' families and well being. Conversely, Roberts, Cox, 
Shannon and Wells (1994) found a weak correlation between psychological distress and spousal 
support in breast cancer patients. These authors concluded that a poor caliber of the 
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pre-existing relationship and the presence of over-solicitous behaviors might increase, rather 
than decrease, distress. Other studies found support to be helpful in come cases and deleterious 
in others (Revenson, Wollman & Felton, 1983), or found no association (Cassileth et aI., 1985), 
or negative association (Neuling and Winefield, 1988) between social support and distress in 
various cancer populations. 
Psychiatric symptoms that are typical of depression and anxiety have been found to be 
related to several factors: declines in the individual's physical health or advancing stage of the 
disease (Akechi et aI., 2000; Bredart et aI., 1999; Craig & Abeloff, 1974; Ganz et aI., 1993; 
Holmes, 1991; Passik et aI., 1995; Portenoy, Thaler, Komblith, McCarthy-Lepore, Friedlander-
Klar, Coyle et aI., 1994; Zabora et aI., 1997), age (Akechi; Bredart; Craig; Ganz; Roth), gender 
(Bredart; Craig), and to psychosocial (Baider & DeNour, 1997; Craig; Ganz; Passik) and 
cultural factors (Craig). In addition, the risk for distress increases as the number of problems 
increase and coping strategies fail (Akechi; Ganz; Passik). Table 3 summarizes the studies 
addressing risk factors related to psychiatric symptoms and distress in cancer populations. 
Physical Symptoms and Prevalence of Psychiatric Diagnosis/Distress in Cancer Patients. 
Troublesome physical symptoms, regardless of whether or not they signal disease 
progression, have been shown to increase anxiety and depression (Akechi et aI., 2000; Bredart 
et aI., 1999; Craig & Abeloff, 1974; Valente et aI., 1994). Researchers (Bredart) found that 
cancer patients with fatigue, persistent nausea and vomiting, and pain were significantly more 
likely than their symptom-free peers to display clinically-diagnosable depression or anxiety. 
When declines in physical health begin to affect the individual's ability to be independent and to 
exercise normal daily routines, further risk for emotional illness develops. One study of 885 
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cancer patients (Akechi) found that when functional status decreased, the level of depression 
and suicidality increased. Others (Bredart; Craig; Valente) found that the number of psychiatric 
symptoms increased as patients became more disabled. Cancer patients that exceed the 
threshold for moderate distress are much more likely to have physical problems severe enough 
to alter their ability to'function in an independent way than their less distressed peers (Ganz et 
aI., 1993). 
Some researchers have attempted to describe the most common problem profiles that 
contribute to distress in various cancer populations. For example, in a sample of 51 outpatients 
(Holmes, 1991) in active treatment for a variety of cancers, the variation among distress scores 
was accounted for by problems associated with the symptoms of fatigue, altered body image, 
low mood, decreased concentration, loss of mobility, pain, and gastrointestinal symptoms. 
Other studies (Passik et aI., 1995; Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-
Klar, Kiyasu et aI., 1994) concur that pain, fatigue, and gastrointestinal symptoms often 
challenge coping resources as they are persistent problems that are often not well treated 
(Holland et aI., 1998). These symptoms are consequently associated with increased risk of 
distress, according to one well-constructed study (Portenoy). In this study of 243 patients with 
ovarian, colon, prostate or breast cancer the researchers found that the mean number of physical 
symptoms contributing to distress was 11. The symptoms were directly and highly correlated 
with the distress level. The most frequently reported symptoms were fatigue, pain, insomnia, 
worry, sadness, and irritability. 
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Table 3 
Risk Factors for Distress in Cancer Populations 
Study II Subjects Measures Method Outcome Factor 
c 
I 
Akechi et ai., 2000 885 Japanese patients with Psychiatric Retrospective chart Psychiatric diagnosis: Increased as 
mixed cancer interview using review Severity of depression functional status 
diagnoses referred to DSM-IV(l994) and suicidal ideation decreased, with 
the Psychiatry criteria for Major age of 60 or older 
Division for Depressive and with later 
Depression Disorder (MDD) stage of the 
disease. 
I 
I 
Baider & DeNour, 1997 283 Israeli stage I and II Brief Symptom Correlational Psychiatric diagnosis: Both BSI and lES 
breast cancer patients Inventory (BSI; surveys BSI score of 63 or scores were 
receiving outpatient Derogatis, 1993) administered on an above psychiatrically directly related to 
follow-up treatment unspecified diagnostic trauma history. 
147 with a trauma Impact of Events outpatient visit 
history and 106 with Scale (rES; lES scores on a Intrusive thoughts 
-
---_._--
-----
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Study 11 Subjects Measures Method Outcome Factor 
no trauma history Horowitz, Wilmer continuum explained 30% of 
& Alvarez, 1979) the variance in BSI 
scores. 
c 
Lack of education 
also contributed 
22% to the 
variance in 
Subjects with BSI 
scores below the 
cutoff 
--- -- --- -
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Study n Subjects Measures Method Outcome Factor 
Bredart et aI., 1999 190 Consecutively Hospital Anxiety Cross-sectional, Psychiatric diagnosis: Significantly more 
admitted Italian and Depressive administered three Score of 14 or more on likely if the patient 
inpatients at a regional Scale (HADS; days prior to the HADS is female, aged 50-
cancer center with Zigmond & Snaith, discharge 65, has diminished 
;' 
mixed cancer 1983) physical 
diagnoses functioning, has 
diminished social 
functioning, is 
fatigued, has 
persistent nausea 
and vomiting, is in 
pain or has the 
perception that 
their health status 
IS poor 
Craig & Abeloff, 1974 30 Consecutively Symptom Cross-sectional, Psychiatric Diagnosis: High symptomatic-
admitted American Checklist-90 (SCL- SCL-90 High symptom group logy is associated 
inpatients with mixed 90; Derogatis, administered within achieved one or more with being 
cancer diagnoses Lipman & Covi, 48 hours of scores of2 standard Caucasian, being 
1973) admission deviations on any female, age of less 
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Study n Subjects Measures Method Outcome Factor 
subscale except than 35 years old, 
somatization low socioeconomic 
status, poor 
"> performance 
status, and dying 
within three 
months of the date 
of the 
measurement 
Ganz et ai., 1993 227 Newly diagnosed Clinical Interview Cross-sectional: Distress: The high-risk 
American breast Cancer Subjects divided CARES subscale groups were older, 
cancer patients Rehabilitation into low medium or scores and KPS scores more likely to be 
participating in a Evaluation System high risk for distress treated with 
randomized National (CARES; Schag, by consensus ofthe chemotherapy, 
Cancer Institute study Heinrich & Ganz, investigating team more likely to be 
of rehabilitation 1984) that included a treated with 
interventions Functional Living social worker, a endocrine therapy, 
Index Cancer medical oncologist had poorer KPS 
(FLIC; Schipper et and a clinical scores, had poorer 
aI.,1984) psychologist scores on the 
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Study n Subjects Measures Method Outcome Factor 
Karnofsky global scale of the 
Performance Status Low risk-minimal CARES and on all 
(KPS; Nickelson et problems, patients subscales. 
aI., 1976) likely to do well , 
Profile of Mood They were 
States (POMS; Medium and high described as out of 
Lorr, Bishop, & risk patients have control or 
McNair, 1965) problems that overwhelmed, 
Global Adjustment require intervention, were more likely 
to Illness (GAlS; differentiated by the to have psychiatric 
Morrow et aI., severity of the histories, social 
1981) problem difficulties, marital 
problems, body 
image concerns 
and money 
problems. 
Moderate risk 
women were 
differentiated from 
high-risk women 
Validation Distress Thermometer 40 
Study n Subjects Measures Method Outcome Factor 
because they had 
better coping 
skills. 
Holmes, 1991 51 American outpatients Symptom Distress Cross-sectional Distress: " ::.. There were no 
with mixed cancer Scale (SDS; Mean symptom significant 
diagnoses. 22 in Holmes, 1991) distress score in differences 
active chemotherapy chemotherapy patients between the 
treatment and 29 in was higher than correlation 
active radiotherapy patients in matrixes of the two 
treatment radiotherapy with groups. In order of 
considerable variation descending 
in the distress scores contribution to the 
variations in the 
scores: fatigue, 
changes in 
appearance, 
changes in mood, 
changes in 
concentration, 
problems with 
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Study n Subjects Measures Method Outcome Factor 
mobility, pain, loss 
of appetite., 
constipation, 
)'';; diarrhea and 
nausea accounted 
for the distress 
scores. 
Passik, Newman, Brennan & 69 Consecutive American BSI (Derogatis, Cross-sectional, Distress: Women with pain 
Tunkel (1995) breast cancer patients 1993) measures given at a Scores on multiple had higher BSI 
following treatment The Derogatis convenient clinic inventories scores and more 
with surgery and/or Sexual Functioning visit functional 
chemotherapy, and/or Inventory (DSFI; interference than 
radiotherapy (Derogatis & women without 
presenting at a Melisaratos, pain. Women with 
lymphedema clinic. 1979). low interpersonal 
No current evidence of IES (Horowitz, support have more 
the disease with Wilner & Alvarez, functional 
lymphedema 1979) interference, 
higher scores on 
the BSI, higher 
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Study n Subjects Measures Method Outcome Factor 
scores on the IES, 
lowered sexual 
drive and less 
satisfaction than 
,-:;' 
women with high 
interpersonal 
support. Women 
with highly 
avoidant coping 
styles have more 
functional 
interference, 
higher scores on 
the BSI and IES, 
poorer body image 
and more pain than 
those with less 
avoidant styles. 
Portenoy, Thaler, Komblith, 243 American inpatients Memorial Cross sectional Distress: Scores of the 
McCarthy-Lepore, Friedlander- and outpatients Symptom survey Regardless of the MSAS 
_._-
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Study n Subjects Measures Method Outcome Factor 
Klar, Coyle et aI., 1994 currently in treatment Assessment Scale tumor stage the 
for ovarian, colon, (MSAS; Portenoy, number of symptoms 
prostate or breast Thaler, Komblith, were directly 
cancer McCarthy-Lepore, associated with distress 
Friedlander-Klar, and inversely 
Kiyasu, 1994) associated with quality 
of life 
The mean number of 
symptoms experienced 
in the sample was 
eleven 
The most common 
symptoms were 
fatigue, pain, insomnia, 
and emotional 
problems 
Roth et aI., 1998 97 American outpatients Distress Cross sectional Distress: Patients who are 
in active treatment for Thermometer (DT; Cutoff score of six elderly and have 
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Study n Subjects Measures Method Outcome Factor 
prostate cancer Holland et aI., associated losses 
2000) are more likely to 
exceed cutoff. 
Zabora et aI., 1997 386 Randomly selected BSI (Derogatis, Cross sectional Distress: Patients at later 
, ~ 
American outpatients 1993) survey: GSI score of the BSI of stages of the 
at 12 oncology Measurements 63 or greater. FLIC disease had 
departments with FLIC (Schipper, taken at active total scores significant declines 
mixed cancer 1984) treatment, in the FLIC scores, 
diagnoses adjunctive therapy, but not in GSI 
no therapy, scores. 
symptom control, or 
~:=:al care 
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There is evidence (Zabora et aI., 1997) that in later stages of the disease the distress 
profile increases due to problems with mobility, pain, and gastrointestinal dysfunction. 
Imminent death is also associated with high distress symptom scores (Craig & Abeloff, 1974) 
although not necessarily with psychiatric diagnoses (Zabora). In fact, distress may exhibit a 
bimodal or trimodal relationship with the stage of the disease. Ford, Fallowfield and Lewis 
(1994) studied 117 cancer patients who just received the news of an initial cancer diagnosis or a 
recurrence of cancer. The sample was assessed three times over the course of the ensuing six 
months. At the time of the first assessment 20% of the sample reported distress. At 3 months, 
the time of the second assessment, 14% of the sample reported distress. By the end of6 months 
only 9% of the sample remained distressed. This pattern suggests that distress may peak at 
times when the patient's perception of the disease changes. In exploring the interaction between 
time since diagnosis and distress, Derogatis et aI., (1979) found that patients in treatment for 
more than 1 year were more depressed, hostile, and cognitively disturbed than patients who 
were earlier in the disease process. 
Age and Psychiatric Symptoms in Cancer Populations 
The relationships between age and psychiatric symptomatology in a heterogeneous 
cancer population are not as clear. A large retrospective study (Akechi et aI., 2000) of Japanese 
cancer patients found that those who were more than 60 years old were more depressed and 
more likely to have suicidal ideation than patients younger than 60. Other studies in American 
cancer populations (Bredart, et aI., 1999, Craig & Abeloff, 1974) found that risk of distress 
increased in the 59 to 65 years-old group and the less than 35 year old cohort in female 
populations. Ganz and colleagues (1993) also found that older women with breast cancer are at 
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more risk for distress and are more incapacitated by the disease than their younger peers. In 
reviewing the distress patterns in a prostate cancer population, Roth and coworkers (1998) 
explained the direct association between advancing age and distress in their population as the 
effect of multiple losses. Their conjecture was that elderly cancer patients were more likely to 
have experienced a recent loss of a spouse or siblings and, in many cases, these losses resulted 
from cancer. However, one study of a cohort of243 patients (Portenoy, Thaler, Kornblith, 
McCarthy-Lepore, Friedlander-Klar, Kiyasu et aI., 1994) found no relationship between age and 
distress scores. The studies' measurement of divergent outcome criteria and cultural diversity 
may account for some of the variation of the descriptions of the relationships found between age 
and distress. Also, adult developmental variations are not well understood (Feldman, 2000) nor 
is the interaction between the type of cancer and age (Holland, 1997). 
The Effect of Gender on Riskfor Psychiatric Symptoms. 
The interaction between risk for psychiatric diagnosis or distress and gender in cancer 
populations is just beginning to be explored. It appears that both psychiatric symptoms and 
distress may differ by gender (Bredart et aI., 1999; Faller, Bulzebruck, Drings & Lang, 1999; 
Ford, Fallowfield & Lewis, 1994; Keller & Henrich, 1999). Recent studies are informative but 
reach contradictory conclusions. In a sample of 103 lung cancer patients, Faller found that 
women reported more symptoms of anxiety while men reported more symptoms of depression. 
In interviewing a cross sectional sample of 246 German cancer patients with mixed diagnoses, 
Keller and Heinrich reported that both genders described similar physical and psychological 
problems. However, 54% of women reported high distress levels while only 28% of men 
complained of high distress. Women reported more psychosomatic symptoms and found 
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physical symptoms to be more troublesome than men did. Context appeared to contribute more 
to distress among men than women. Ford and colleagues found that the pattern of anxiety and 
depression differed by gender over time, as changes in the course of the disease occurred. Last, 
Bredart and associates found that more women than men with cancer exceeded the score for 
psychiatric symptomatology on the HADS (Zigmond & Snaith, 1983). 
Impact of other Variables on Riskfor Distress Associated with Cancer 
The literature is replete with discussions about the impact of psychosocial and 
demographic variables on the risk for psychiatric symptomatology and distress in cancer 
populations (Baider & DeN our, 1997; Bielauskas & Garron, 1982; Bredart et aI., 1999; 
Costantini et aI., 1999; Craig & Abeloff, 1974; Dattore et aI., 1980; Derogatis, Abeloff & 
Melisaratos, 1979; Everson et aI., 1996; Faller et aI., 1999; Farber, Weinerman & Kuypers, 
1983; Keller & Henrich, 1999; Lloyd, 1979; Mahon & Casperson, 1995; Passik et aI., 1995; 
Persky, Kempthorne-Rawson & Shekelle 1987; Schwartz, Lerman, Miller, Daly & Masny, 
1995; Tope et aI., 1993). Some articles summarize clinical or observational experience and 
draw a large number of conclusions about a plethora of variables ranging from the effect of the 
loss of a primary relationship to the effect of financial problems (Bieliaukas; Lloyd). In terms 
of psychiatric symptoms, Baider and DeNour reported that less educated subjects experienced 
more emotional difficulties. Low socioeconomic status (Craig) also correlates directly with 
affective difficulties in cancer populations. The risk of distress has been found to increase with 
psychiatric history (Ganz et aI., 1993), inadequate social networks (Ganz et aI., 1993; Passik), 
marital difficulties (Ganz), financial problems (Ganz), and sexual difficulties (Passik). Cultural 
Validation Distress Thermometer 48 
biases also influence the distress profile in ways that are not well understood. The risk for 
emotional symptoms in a Canadian cancer population was estimated to be 34.4% (Faller et al., 
1999), close to the incidence most usually reported in American populations. However, Hurny 
and his co-researchers (1993) found significant differences between a German and an Italian 
population both in the number of problems reported and the distress associated with the reported 
problems. The Italian population scored higher than the German population on both measures. 
This beginning work does little to add to our knowledge of the potential interaction among 
factors and lacks the breadth necessary to draw any but the most preliminary conclusions. 
The Role a/Coping Responses. 
Studies of newly diagnosed cancer patients demonstrate that the most effective coping 
responses, are "confronting" responses. These responses include: use of religion, adopting a 
positive approach, changing perceptions in a way that seems beneficial, rehearsing emotions 
anticipated in response to event and consequences, planning positive events and activities, and 
exercising imaginative control over the outcome. They are associated with enhanced 
psychological well being (Behen & Rodrique, 1994; Burgess, Morris & Pettingale., 1988; 
Morrison, Hislop, Mears & Kan 1991; Taylor et al., 1991). Conversely, a study of patients with 
advanced cancer (Felton, Revenson & Hinrichsen, 1984) found little relationship between 
coping resources and psychological adjustment. This discrepancy may indicate a trend for 
coping skills to diminish in effectiveness as physiologic compromise increases. Taylor and 
colleagues also found that adaptive coping responses were dependent upon the stage of the 
illness and the prognosis. For persons early in the illness, with a good prognosis, coping 
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included reliance on others. For those with a poor prognosis, self-generated feelings of control 
were most adaptive. An awareness of the factors that increase vulnerability for distress will 
help to identify at risk portions of the whole cancer population. Now let us turn to the 
consideration of how best to measure distress both in the at risk and general cancer popUlations. 
Distress Screening Tools 
Psychometric Requirements. 
The value of a screening instrument in both clinical and research applications is 
determined by its psychometric properties and clinical utility. Two major psychometric 
questions must be answered before researchers and clinicians can be confident that an 
instrument acceptably measures the variable in question: (a) Is the screening-tool a reliable or 
consistent measure ofthe property or attribute it claims to measure?; and (b) Is the tool a valid 
measure, or to what degree does it really measure what it claims to measure? (Aiken, 1996; 
Keppel, 1991; Nunnally & Bernstein, 1992) 
The question addressing the instrument's reliability further focuses on the stability of the 
results produced by the screening tool and the consistency of its items. Results are stable if the 
measure produces the same outcome when given repeatedly to the same subject, ifthe measure 
produces the same results regardless of the arrangement of items and if two or more raters using 
the instrument to measure the variable in one particular subject arrive at the same results. 
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Test-retest, parallel forms and inter-rater reliability analyses gauge the stability oftest results, 
over time, within the arrangement of items and between two or more raters respectively (Aiken, 
1996; Grant et aI., 1990; Nunnally & Bernstein, 1992). 
As previously discussed, the distress screening instruments considered here are all 
constructed in a self-report format. Inter-rater reliability is not a relevant parameter for the 
evaluation of self-administered screening tools. Stability of scores is of interest if the attribute 
measured changes little over time. For example a measurement of height is expected to have 
excellent test-retest reliability. It is a somewhat irrelevant concept when the attribute being 
measured is a trait whose expression is expected to change over time, thus producing unstable, 
rather than stable, measurements. For example a measurement of weight in a growing infant 
would be expected to have little or no test-retest reliability when measured over time. As 
defined, distress is a trait-like variable and in the measurement of distress, test-retest reliability 
analysis produces a spurious statistic of little use for evaluating distress assessment instruments 
(Aiken, 1996; Grant et aI., 1990; Nunnally & Bernstein, 1992). 
The second tenant of the tool's reliability examines the consistency of performance of a 
group of individuals across the items in a measure. Responses on consistent items will be 
highly correlated with each other. The more a measure is internally consistent, the more likely 
that all of the items quantify the same concept. Internal consistency is reported as an alpha 
coefficient and a value of. 70 or greater increases confidence that the instrument is measuring 
just one concept. (Grant et aI., 1990) A good measure of distress would have an alpha 
coefficient of. 70 or greater. 
A second branch psychometric evaluation attempts to define the structure of components 
that contribute to the formation of the concept being measured. This analysis examines the 
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relative correlation among and between responses to the scale's items and proposes a solution to 
account for the variance among the item scores in a group of individuals. The statistical 
approach for this research is factor or cluster analysis. In accordance with previous research 
(Coyle et aI., 1996; deHaes et aI., 1990; Hurny et aI., 1993; McCorkle & Young, 1978; 
O'Boyle & Waldron', 1997; Peruselli, et aI., 1993; Rhodes et aI, 2000; Schag et aI., 1991; Schag 
& Heinrich, 1990; Schipper et aI., 1984; Sollner et aI., 1998), a good measure of distress should 
include factors related to physical problems, to emotional problems, to practical problems and to 
interpersonal problems, or should display a four-cluster solution. 
After the instrument's reliability is established, it is examined in an attempt to ascertain 
that it is measuring what it claims to measure. There are three major types of validity: content, 
construct and criterion. A tool's content validity refers to the extent to which the items 
adequately sample the content area in question. It is usually either established by agreement of 
a panel of experts in the field or through extensive literature review. When a panel of experts 
establishes the appropriate content, a content validity index (CVI) may be reported. The closer 
to 1.0 the CVI, the higher the agreement among the panel of experts (Grant et aI., 1990). The 
process for identifying the content of the distress-screening tool should be published in a report 
of an early trial of the tool. 
Construct validity refers to the ability of a tool to perform according to theoretical 
predictions. A tool that is sensitive to differences between groups and demonstrates those 
differences in a predictable direction exhibits construct validity (Aiken, 1996; Grant et aI., 1990; 
Nunnally & Bernstein, 1992). For example, distress scores should be higher in the cancer 
population than in a "normal" population. Also patients with relatively few symptoms should 
be less distressed than those with many symptoms. Since distress changes over the course of 
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the cancer experience (Ford et aI., 1995), and is problematic at sub-clinical levels (Holland et 
aI., 2000), an adequate distress measure should be sensitive to the current situation of the 
patient. 
Finally, criterion validity refers to a relationship between an instrument and an outside 
indicator. There are two subtypes of criterion validity, concurrent and predictive. Concurrent 
validity refers to the subject's performance on the instrument and on another indicator that 
measures the same or a parallel concept, when the measures are administered at the same time. 
If both indicators measure the same concept, the scores on the instruments should correlate 
highly or display convergent validity. If the indicators measure on different concepts, the scores 
on the instruments in question should produce low or moderate correlation or divergent validity. 
(Aiken, 1996; Grant et aI., 1990; Nunnally & Bernstein, 1992). Distress tools might exhibit 
convergent validity with other measures of distress and divergent validity with measurements of 
quality of life, psychiatric symptoms or resiliency in cancer populations. By contrast, predictive 
validity refers the correlation between sets of data collected at different times. One set of data 
may be used to predict the scores on another measure. The most usual example of this is the use 
of scholastic aptitude scores to predict college performance. Distress scores have been used to 
predict morbidity (Fawsy, 1994; Holland, 1997; Lloyd, 1979; McDaniel et aI., 1995) and 
mortality in cancer populations (Derogatis et aI., 1979; Faller et aI., 1999; Fawsy, 1994; 
Morrison & Paffenbarger, 1981). 
Additionally, a sufficient distress screening scale should meet criteria for clinical utility 
constructed by researchers (Barg et aI., 1994; Finlay & Dunlop, 1994; Grant et aI., 1990). To 
review, the criteria identified include: (a) the tool is specific for the cancer population; (b) it is 
self-administered and easily interpreted; (c) it identifies the patient's risk for psychosocial 
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problems; (d) it is short with little response burden; (e) it serves to triage patients to appropriate 
services; and (f) it is capable of identifying cancer-related problems in multiple dimensions. 
The review of the literature for instruments that measure distress in cancer populations 
yielded six instruments in varying stages of development. In all six, distress is an emotional 
reaction to unresolved problems associated with the cancer experience, rather than a psychiatric 
symptom or a parameter of quality of life. They are the Rotterdam Symptom Checklist 
(deHaes, van Knippenberg, & Neijt, 1990), the Modified Symptom Distress Scale (Holmes, 
1991), the Adapted Symptom Distress Scale-2 (Rhodes et aI., 2000), the Memorial Symptom 
Assessment Scale (Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Coyle, 
1994), the Memorial Symptom Assessment Scale-Short Form (Chang, Hwang, Corpion & 
Feuerman, 1997) and the Edmonton Assessment Scale (Bruera, Kuehn, Miller, Selmser, & 
Macmillan, 1991). The scales are reviewed below. 
Rotterdam Symptom Checklist (RSC). 
The RSC (deHaes, vanKnippenberg & Neijt, 1990; see Appendix B) is a 38-item 
checklist that measures distress related to cancer specific symptoms in three domains of 
functioning. Patients are asked to report the degree that physical, psychological or functional 
symptoms have bothered them over the past week. The administration time is approximately 15 
minutes. Scores are reported on a 4-point Likert-type scale from "not at all" to "very much". 
The scale was constructed by secondary analysis (deHaes et aI., 1990) of items from the Dutch 
version of the Symptom Distress Scale (McCorkle & Young, 1978), the Hopkins Symptom 
Checklist (Derogatis, Lipman, Rickels, Uhlenhuth & Covi, 1974) and a breast cancer distress 
scale (deHaes et aI., 1996). Scale items were selected on the basis of factor loading in the initial 
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sample, for their relevance to the diagnosis as judged by a panel of experts and according to the 
distribution of answers in the validation study (deHaes, Pruyn & vanKnippenberg, 1983). The 
scale produces subscale scores for physical and psychological distress and for overall activity 
level. It also produces a single overall score that estimates the patient's quality oflife. 
The RSC's items exhibited internal consistency in groups of heterogeneous Dutch 
cancer patients who were treated with chemotherapy (deHaes et aI., 1983), in a large cross-
cultural sample of heterogeneous cancer patients treated with chemotherapy (Jones & Coleman, 
1993), and in samples of newly diagnosed heterogeneous Dutch and Scottish cancer patients 
(Soukop et aI., 1992). The Chronbach's Alpha (CA) for psychological symptoms ranged from 
.85 to .94, while the statistic for physical symptoms ranged from .80 to .87, and the CA ranged 
from .61 to .95 for activity level. Further, the overall quality of life score was related to all 
subscales; for physical symptoms ~=.75 to .79, for psychological symptoms! =.56 to .65 and 
for activity level! =.58 (deHaes et aI., 1996). 
Factor analysis in the original sample (deHaes et aI., 1983) described a two-factor model 
consisting of physical (37.5% ) and psychological symptoms (28%) of the variance. In other 
samples (Jones & Coleman, 1993; Soukop et aI., 1992), factors related to fatigue and 
gastrointestinal symptoms were identified dependent upon the time in the course of the disease 
when the measurement was taken. 
The scale's construct validity is relatively well established. The subscale scores for 
physical distress were correlated with the physical distress items on the Medical Outcome 
Study-36 (Ware & Sherbourne, 1992), while the psychological distress subscale correlated well 
with the HADS (Zigmond & Snaith, 1983) and the Adjustment to Illness Scale (Morrow et aI., 
1981) in a sample of 216 cancer patients who exhibited evidence of psychopathology (Watson 
Validation Distress Thermometer 55 
et aI., 1992). Paci (1992) also found the psychological subscale to be related to the scores on 
the State-Trait Anxiety Scale (r =.70; Spielberg, 1985) in a sample of 278 heterogeneous cancer 
patients undergoing active treatment. 
The checklist has been shown to be a sensitive measure distress in a number of clinical 
trials in cancer populations. Souhami and colleagues (1997) used the RSC to report differences 
in distress between subjects treated with oral and intravenous palliation for lung cancer. They 
found that intravenous chemotherapy in this sample of terminally ill patients was associated 
with the same or less distress as oral chemotherapy and with prolonged survival. Other authors 
(Macbeth et aI., 1996) found that the psychological distress subscales of the RSC discriminated 
between groups receiving low-dose radiotherapy and those receiving high-dose radiotherapy in 
a sample of 250 small cell lung cancer patients. Patients receiving the high-dose radiotherapy 
were less distressed than patients receiving low dose therapy. In additional studies the RSC 
defined abnormal distress levels in a group of breast cancer patients treated with Cisplatinum 
(deHaes, 1996), and differentiated between cancer populations and disease-free popUlations 
(Watson et aI., 1992) 
Adapted Symptom Distress Scale-2 (ASDS-2). 
The ASDS-2 (Rhodes et aI., 2000; see Appendix E) is a 31-item self-report inventory of 
distress associated with 14 common cancer symptoms. Each item is rated on a 5-point Likert 
scale with 0 being no occurrence of the symptom and 4 being a symptom that causes the most 
distress. It is an adaptation of the SDS (McCorkle & Young, 1978) designed to more accurately 
represent the spectrum of common cancer symptoms and to clarify certain confusing questions. 
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The symptoms included are: nausea, vomiting, pain, eating, sleep, fatigue, bowel elimination, 
breathing, coughing, lacrimination, changes in body temperature, appearance and restlessness. 
The instrument yields a total score, a score for symptom distress and six sub-scale scores. The 
sub-scales include gasterointestional symptoms, pain/discomfort, respiratory symptoms, 
concentration and appearance. 
The scale was developed by deleting items from the Adapted Distress Scale-l (Rhodes, 
Watson & Johnson, 1984) that exhibited only moderate reliability and adding three items: 
lacrimation, changes in body temperature and restlessness, based on clinical observation and 
reports of cancer patients (Rhodes et aI., 2000). 
The tool exhibited good internal consistency in a sample of 354 adults (82 
medical-surgical patients, 175 oncology inpatients and 95 healthy adults). The CA was 0.91 for 
total symptom experience, 0.76 for total distress and 0.90 for total occurrence. Sub-scale 
reliabilities ranged from ~ = 0.64 to ~ = 0.83. (Rhodes et aI., 2000). 
Other reported psychometric parameters include the scale's test-retest reliability and 
content validity. The test-retest reliability with a 2-week interval in 28 hospitalized 
medical surgical patients was ~ = 0.92 (Q < .001; Rhodes). Content validity was supported via 
review of the literature and through cancer patient's reports about symptoms (Rhodes et aI., 
2000). 
The scale discriminated between the well group and the oncology patients (2 < .001), but 
not between the well group and the medical-surgical patients for total symptom experience. It 
discriminated among all three groups for symptom occurrence, but did not discriminate between 
the oncology and medical surgical group in terms of symptom distress scores. (Rhodes et aI., 
2000) There are no reports of the scale's construct validity. 
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Memorial Symptom Assessment Scale (MSAS). 
The MSAS (Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et 
aI, 1994; see Appendix F) is a 33-item Likert scale instrument that measures the severity, 
frequency and distreSs associated with symptoms experienced by cancer patients. The list of 
symptoms was compiled through a review of the cancer literature and modified following an 
initial trial of the scale in a sample of 297 cancer patients. The internal consistency was high for 
the prevalence of symptoms and the psychological state sub-scales (a = .88 and .83) and for the 
pain sub-scales (a =.87). It was moderate for gastrointestinal distress (a =.75) and low for 
symptoms with less prevalence (a =.58). 
In the same study (Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, 
Kiyasu et aI, 1994) factor analysis yielded a principle component that reflected the overall 
symptomatology and accounted for 24% of the variance among scores and two major factors: 
psychological symptoms and physical symptoms. Each of these factors can be sub-divided into 
two smaller factors. Content validity estimates focused on the role of the dimensions of 
severity, frequency and distress for each symptom in order to evaluate the potential of 
multidimensional assessment of each symptom. Mean severity and frequency scores were 
correlated (r = .80) across symptoms as were mean severity and distress scores (r = .70). 
Conversely, the correlation between mean frequency and distress scores was low. Further 
canonical correlation analysis suggested that distress was the most informative dimension in the 
multidimensional approach. 
The tool differentiated between cancer inpatients and outpatients (Chang, Hwang & 
Kasimis, 1995; Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Coyle et aI, 
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1994; Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et aI, 1994). In 
all studies inpatients reported significantly higher MSMS total scores than outpatients. It also 
discriminated among patients without cancer, those with local disease and those with distant 
metastatic disease (Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu). 
Those with distant metastatic disease reported the highest scores. Patients with local disease 
reported moderate scores, and cancer-free subjects reported low scores. 
In one population, highly significant correlations (2 < .001) with scores on the Memorial 
Pain Assessment Card (MPAC; Fishman, Pasternak, Wallenstein, Houde, Holland & Foley, 
1987), the Revised Rand Mental Health Inventory (RAND; Veit & Ware, 1983), the Functional 
Living Index Cancer (FLIC; Schipper et aI., 1984), the Symptom Distress Scale (SDS; 
McCorkle & Young, 1978), and the Karnofsky Performance Scale (KPS; Nickelson et aI., 1976) 
were found (Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et aI, 
1994). These correlations were for the total MSAS scores, the single dimensions of severity, 
frequency and distress and for major symptom groups averaged across dimension. The scale's 
predictive validity has not been reported. 
The MSAS (Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et 
aI, 1994) was used by researchers to measure quality of life in advanced breast cancer patients 
receiving chemotherapy by researchers (Seidman et ai., 1995). The researchers found that 
tumor responses to chemotherapy were associated with changes on MSAS scores. It was used 
to assess distress in clinical cancer trials (Ingham, Seidman, Yao, Lepore & Portenoy, 1996). 
The scale differentiated the distress levels in ovarian cancer patients with a KPS (Nickelson et 
aI., 1976) score of 80 or less from those with a KPS (Nickelson) score of 90 or more (Kornblith 
et aI., 1995). It was used to quantify the effect of hydrocortisone treatment in 21 hormone-
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refractory prostate cancer patients on quality oflife (Curley, Liebertz, Portenoy, Kelly & Scher, 
1994). Curley and colleagues found an inverse relationship between Prostate Specific Antigen 
(PSA) levels and MSAS scores. The MSAS has also been used in additional research 
applications (DuPen et ai., 1999; Hann, Jacobsen, Martin, Kronish, Azzarello & Fields 1997; 
Harrison et ai., 1997; Payne, Mathias, Pasta, Wanke, Williams & Mahmoud 1999) to quantify 
distress and quality of life in cancer populations. 
Memorial Symptom Assessment Scale- Short Form (MSAS-SF). 
The MSAS-SF (Chang et ai., 1997) is an abbreviated version of the MSAS that 
measures symptoms only in the distress and frequency dimensions. Chang and his colleagues 
trialed the tool in a sample of 75 mixed diagnoses cancer patients. They reported that all of the 
MSAS summary scales were reliable on the MSAS-SF (~ = .94 for the total symptom index, ~ = 
.73 for the physical symptom sub-scale and ~ = .67 for the psychological symptom sub-scale). 
Criterion concurrent validity for the general score and physical and emotional well-being 
sub-scales with the Functional Assessment Cancer Therapy (FACT; Cella et ai., 1993 ) was 
established to be 2 < .001. No predictive validity or current usage of this scale is reported. 
Edmonton Symptom Assessment Scale (ESAS). 
The ESAS (Bruera et al., 1991; See Appendix G) consists of nine 100-mm visual 
analogue scales representing symptoms or activities important to cancer patients in the terminal 
phase of the illness. These parameters include numerous symptoms: pain, inactivity, nausea, 
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depression, anxiety, drowsiness, appetite, shortness of breath and sensation of well being. It 
was designed for use in a palliative care population. Symptoms are either self-reported or 
assessed by professional staff twice daily and recorded on a graph that compares results across 
21 days. Scores are repOlied for each symptom and a global performance rating is assigned. 
Summing the individual scores produces a global distress score. Scores are directly related to 
symptom severity. 
A panel of palliative care experts (Bruera et al., 1991) identified the parameters included 
on the scale. Tool's psychometric properties are just beginning to be reported. A small sample 
of 22 mixed diagnosis palliative care cancer patients (Philip, Smith, Craft & Lickiss, 1998) 
produced scores on the Rotterdam Symptom Checklist (deHaes et al., 1983) that were highly 
correlated with their scores on the ESAS supporting the ESAS's concurrent validity. A later 
prospective study in 240 palliative care cancer patients (Chang, Hwang & Feuerman, 2000) 
found that the ESAS distress score correlated most closely with the physical symptom subscales 
of the Functional Assessment of Cancer Therapy (FACT; Cella et al., 1993) and MSAS and with 
the KPS (Nickelson et al., 1976) 
The individual items and summary scores exhibited good internal consistency and 
correlated well with like items on the MSAS (Portenoy, Thaler, Kornblith, McCarthy-Lepore, 
Friedlander-Klar, Kiyasu et aI, 1994) and FACT (Cella et al., 1993; Chang et al., 2000). Test 
re-test reliability was better at 2 days but the correlation was smaller at the end of a week, 
suggesting that the scale does not measure a steady trait. The distress score also tends to reflect 
the patient's physical well being. 
The ESAS (Bruera et aI., 1991) scores discriminated between a group of patients who 
died and a group who were discharged from a palliative care unit (Rees, Hardy, Ling, Broadley 
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& A'Hern, 1998). Scores for both groups worsened over the 5 days of data collection, and there 
were no significant differences between the groups on the overall distress scores. However, the 
group that was discharged experienced a significant improvement in pain scores, while the 
group that died showed a significant deterioration in activity, drowsiness and appetite prior to 
death. It has also been used to audit the effectiveness of symptom control in a sample of 
palliative care patients (Dudgeon, Hados & Clinch, 1999) and to describe relationships among 
medication, demographic and symptom profiles in a palliative care population (Jenkins, Schultz, 
Hanson & Bruera, 2000). 
Summary. 
All of the self report measures of distress reviewed have acceptable internal consistency, 
and most have respectable psychometric evidence of their validity as measures of distress in 
cancer populations. In addition, they meet at least four of the seven clinical criteria (Barg et aI., 
1994; Finlay & Dunlop, 1994; Grant et aI., 1990) previously described as desirable for a 
screening tool. All the measures are specific for cancer populations; they are self-administered; 
they identify specific psychosocial problems; and they measure multiple dimensions. However, 
the need for a general screening tool for distress in the large general cancer population raises 
several challenges that cannot be addressed by the existing instruments. 
First, recall that cancer is not one but rather some 200 different diseases (Holland et aI., 
1998). Therefore, symptoms in the general cancer population are highly variable. It is likely 
that some distressing low incidence symptoms will not be addressed by a scale produced 
through review of the literature for common symptoms. For example, patients with tumors 
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surrounding or impinging on the optic nerve may experience distressing visual losses. This 
source of distress will be missed by all of the reviewed scales, while the DT (Holland et al., 
2000) provides for a direct analogue measure of distress itself and the option to respond to an 
"other" category if, or when, symptoms do not apply. 
Second, variability of symptoms that contribute to distress is evident in the divergence 
of factor structures discovered when a tool is administered to different cancer populations and in 
different cultures. Some authors (Cooley, 2000; Friedman, Webb, Richards & PIon, 1999; 
Sturgeon et aI., 1998) have proposed that distress scales for specific types of cancer might solve 
this problem. This solution may be appropriate in research settings or in arenas that deal 
exclusively with specific cancer diagnoses. It does little to address the need for a distress-
screening instrument to be used in large heterogeneous cancer populations. The DT's (Holland 
et al., 2000) approach of screening for general distress and abandoning the notion of quantifying 
distress associated with problems identified through professional consensus may offer a viable 
alternative for general cancer populations. 
The response burden may also be problematic in cancer populations with high 
fatigability (Derogatis, 1993). In recognition of this issue, attempts have been made to shorten 
the screening tools. For example, Chang and colleagues (1997) shortened the MSAS to reduce 
response burden. Even this shortened form calls for judgment of individual symptoms in 
several dimensions and requires five to ten minutes for completion. It lacks depth in its reported 
validity profile and there has been little use in research. The DT (Holland et aI., 2000) requires 
60 seconds or less for administration, thus poses little threat of response burden. 
All of the tools reviewed previously require the calculation of sub-scale and aggregate 
scores. Although these calculations may be simple compared to the scoring of psychological 
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tests, scoring requires staff training and time. It is possible that insufficient man-hours for 
scoring and follow up has been a barrier to distress screening. Additionally, staff resistance to 
work burden may deter efforts to screen all patients. The DT (Holland et aI., 2000) produces an 
easily interpretable score that requires no preliminary calculation. 
Last, only the DT scores lend themselves to a triage system as described in the NCCN 
practice guidelines (Holland, et aI., 2000). In this system, referrals to appropriate health care 
providers are made according to the level of distress reported. Referrals generated in response 
to the range of the patient's distress score vary from requests for peer support to psychiatric 
intervention. 
Since the DT (Holland et aI., 2000) has not been subject to psychometric analysis it 
seems prudent to proceed with an evaluation of its performance in a large heterogeneous cancer 
population. 
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Hypotheses 
The Distress Thermometer (Holland et aI., 2000) is designed to measure distress as 
defined by the NCCN in general cancer populations. Recall that the NCCN (2000) definition of 
distress is: 
An unpleasant emotional experience of a psychological (cognitive, behavioral, 
emotional), social, and/or spiritual nature that may interfere with the ability to cope 
effectively with cancer and its treatment. Distress extends along a continuum, ranging 
from common normal feelings of vulnerability, sadness, and fears to problems that can 
become disabling, such as depression, anxiety, panic, social isolation, and spiritual 
crisis. (p. DIS-2) 
The foUowing four hypotheses were tested in this research. 
Hypothesis One. 
The scores on for the sample will be reliable (~ ::: .7), and a factor analysis using the 
items of the DT (Holland et aI., 2000) representing multiple problems that are associated with 
distress in the cancer population will yield four homogenous subgroups of items. Problems 
routinely reported to produce distress in cancer populations are physical problems (Finlay & 
Dunlop, 1994; Ganz et aI., 1993; Q'Boyle & Waldron, 1997; Rhodes et aI., 2000; Schag & 
Heinrich, 1990; Sollner et aI., 1998), emotional problems (Finlay; Ganz; Q'Boyle; Rhodes; 
Schag; SoUner), practical problems (Finley; Ganz; McCorkle & Young, 1978; Roth et aI., 
1998; Schag) and interpersonal problems (Finlay; Ganz; Q'Boyle; Rhodes; Schag; SoUner). 
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The identified factors will exhibit adequate internal consistency (~::: .5) and will be directly and 
significantly correlated (2::: .01) with the total distress score as measured on the analogue 
thermometer. 
Hypothesis Two./ 
The NCCN Distress Thermometer total score obtained in a general cancer patient 
population will display a positive relationship with the Rotterdam Symptom Checklist total 
distress score (deHaes et aI., 1990). The RSC (deHaes) is a measure of distress associated with 
38 common cancer symptoms in three domains of the four domains addressed by the DT 
(Holland). It does not address distress associated with interpersonal problems. As with most 
measures of distress in cancer populations (Finlay & Dunlop, 1994; Ganz et aI., 1993; O'Boyle 
& Waldron, 1997; Rhodes et aI., 2000; Schag & Heinrich, 1990; Sollner et aI., 1998) there is no 
spiritual domain included on the RSC (deHaes). The RSC (deHaes) total score sums the 
distress profile, as does the score on the Distress Thermometer, and has been found to be a valid 
measurement of distress in cancer populations (Watson et aI., 1992). High correlation between 
the scores obtained in the study sample on the two instruments suggests that the DT displays 
concurrent validity. 
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Hypothesis Three. 
The Distress Thermometer (Holland et aI., 2000) total score will display a positive 
relationship with the FLIC total score (Schipper et aI., 1984). The FLIC is a valid measure of 
functional status in cancer populations (Schipper). 
Hypothesis Four. 
Total scores on the NCCN Distress Thermometer (Holland et aI., 2000) will be highly 
correlated with high Brief Symptom Inventory (BSI; Derogatis, 1993) global severity index 
(GSI) scores. The BSI is a valid measurement of psychiatric symptoms in cancer populations 
(Derogatis, 1982) and the global severity score best indicates the amount of distress associated 
with the symptoms reported by respondents to the BSI. 
Additionally, highly distressed members of the sample (scoring 7-10) are likely to report 
high GSI scores and undistressed (scoring 0-3) respondents are apt to report a low GSI score, so 
a significant correlation (2 .:s .01) between the high and low distress scores and the GSI will be 
found. It is likely that some patients who meet the criterion for a diagnosis of distress (scoring 
4-7 on the DT) in the sample will report low BSI scores, others will report moderate scores and 
still others high scores. Thus a lack of correlation between BSI (Derogatis) scores and moderate 
DT total scores will demonstrate divergent validity. 
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Methods 
Overview a/the Research Design 
In this study a craSs sectional psychometric design in a sample of heterogeneous cancer 
patients was analyzed. This research tested some of the properties of the NCCN Distress 
Thermometer (Holland et aI., 2000) in the sample's responses. A principal components factor 
analysis with varimax rotation was performed to identify the factors underlying total distress 
scores in this population. Convergent validity was tested by comparing the DT (Holland) total 
score with the total scores from both the RSC (deHaes, van Knippenberg & Neijt, 1990), a 
well-established measure of distress in cancer populations, and the FLIC (Schipper et aI., 1984), 
a measure of cancer patients' quality of life. To test divergent validity, the total, low, moderate 
and high total scores of the DT (Holland) were compared with global severity index(GSI) scores 
of the BSI, a score that quantifies distress associated with psychiatric symptoms (Derogatis, 
1993). 
Measures and Apparatus 
The NCCN Distress Thermometer (DT; Holland et al., 2000; see Appendix A). 
An analogue scale anchored at one end by a zero rating indicating no distress, and at the 
other by a rating of 10 or severe distress. Scores are reported as a single line drawn through an 
integer on the thermometer and either yes or no responses to 33 problems commonly 
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experienced by cancer patients; distress associated with the problems endorsed contributes to 
the total distress recorded as a summary score on the analogue scale. A panel of expert 
psycho-oncology practitioners from 18 comprehensive cancer centers developed the scale in 
1998. It received a class "2A consensus" from the group (NCCN, 2000). The category 2A 
consensus means thaUhere is uniform NCCN consensus, based on low-level evidence, 
including clinical experience, that the recommendation is appropriate. It was designed to be an 
inexpensive, easily administered tool for broad screening in cancer popUlations and to lead to 
appropriate triage for the purpose of distress treatment. The administration time is less than a 
minute. Its scores demonstrated a 74.4% concordance with the scores on the HADS (Zigmond 
& Snaith, 1983) in a sample of 121 prostate cancer patients (Roth et al.,1998). Its remaining 
psychometric properties have not been reported. As the tool is early in development, there are 
no reports of studies employing the DT (Holland) to date. 
The Brief Symptom Inventory. (BS1; Derogatis, 1993,' see Appendix D). 
The BSI is a 53-item, shortened version of the SCL-90 (Derogatis & Melisaratos, 1983). 
It is designed to measure psychological symptomatology on a 5-point Likert scale of 0, (not at 
all) to 4, (extremely). The test yields three global indices: the Global Severity Index (GSI), the 
Positive Symptom Total (PST) and the Positive Symptom Distress Index (PSDI) and subscores 
on nine symptom dimensions. The test takes eight to ten minutes to administer. Its internal 
consistency, test-retest reliability, convergent and divergent validity, equivalence to the SCL-90 
and factor structure have been tested and found to be acceptable (Derogatis, 1982). Stefanek, 
Derogatis and Shaw (1987) found the incidence of psychological distress in an outpatient 
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population of 126 cancer patients to be 23.8% using the BSI (Derogatis). This demonstrates its 
sensitivity for measurement of psychological distress. in cancer populations. Edwards, 
DiClemente and Samuels (1985) differentiated the psychological profiles of long-term cancer 
survivors from those of short-term survivors based on BSI (Derogatis) scores. Two studies 
(Schain, Wellisch, Pasnau & Landsverk, 1983; Wellisch, Gritz, Schain, Wang & Siau, 1991) 
evaluated distress profiles in breast cancer populations with the BSI and found differences 
among study groups. Finally, Shover, Fife and Gershenson (1989) employed the BSI 
(Derogatis) to evaluate treatment effects in a sample of cervical cancer patients. 
The Rotterdam Symptom Checklist. (RSl; deHaes et aI., 1990; see Appendix B) 
A 38-item distress checklist that measures three domains of functioning. Patients are 
asked to report the degree that physical, psychological or functional symptoms have bothered 
them during the past week. Scores are reported on a 4-point Likert type scale from 0 (not at all) 
to 3 (very much). It is internally consistent and exhibits concurrent validity with the HADS 
(Zigmond & Snaith, 1983) and the Adjustment to Illness Scale (AIS; Morrow et aI., 1981) in a 
cancer population that exhibited evidence of psychopathology (Watson et aI., 1992). It has been 
shown to be a sensitive measure of distress in a number of clinical trials in cancer populations 
(Macbeth et aI., 1996; Souhami et aI., 1997; Stephens et aI, 1997) (See previous section entitled 
Review of Distress Tools for further discussion). 
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The Functional Living Index-Cancer. (FLIC; Schipper et al., 1984,' see Appendix C). 
The index is a 22-item cancer-specific quality of life questionnaire. Items are self-rated 
on a linear analogue scale that measures variables in five domains: physical well being, 
emotional state, sociability, family situation and nausea. The scale is easy to administer and 
takes less than 10 minutes to complete. The FLIC (Schipper) was found to be a reliable 
measure in a population of 530 cancer patients (Morrow et aI., 1992). The factor structure was 
consistent across three different cancer populations (Schipper et aI., 1984). Concurrent 
validation studies (Schipper) with the Karnofsky Performance Index (Nickelson et aI., 1976), 
the Beck Depression Scale (Beck, Steer, & Garbin, 1988), the Spielberg State-Trait Anxiety 
Questionnaire (Spielberg, 1985), the scaled version of The General Health Questionnaire 
(Goldberg, 1992) and the McGill/Melzack Pain Index found that the PLIC (Schipper) accounted 
for a high percentage of the sample variation by principle components. The questionnaire's 
scores in another sample were independent of measures of symptoms and anxiety (Morrow, 
Lindke & Black, 1992). It has been used as a measure of quality of life in a wide variety of 
clinical studies in cancer populations. 
The Statistical Package for Social Sciences (SPSS version 10.0,2000) was used for the 
analysis of all data. 
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Procedures 
Testing Materials. 
Testing materials were assembled in packets that included: (a) an instruction sheet (see 
Appendix H); (b) a demographic sheet (see Appendix I); ( c) the DT (Holland et ai., 1998); (d) 
the BSI (Derogatis, 1993); (e) the RSC (deHaes et ai., 1990); (f) the PLIC (Schipper et ai., 
1984); and (g) an 8 liz x 11 inch manila envelope. Tests were in identical order in each packet. 
Each item was labeled with a unique five-digit code. Packet codes began at 20001 and ended 
with 20250. Every Tuesday during the data collection period, the principal investigator 
distributed test packets and a supply of consent letters to the areas involved in the project. 
Inclusion of Study Participants and Informed Consent. 
To be included in the study, subjects were at least 18 years old, and able to do all of the 
following: see well enough to read the items, speak and read English, hold a writing implement 
and be aware of their cancer diagnosis. Demented, delirious or psychotic patients were 
excluded from the study. In outpatient areas, a researcher (either the principal investigator or 
one of nine registered nurses who had been trained to obtain consent and collect data) 
approached patients when they registered for treatment. The researcher checked the birth date 
on the patient's identification plate to confirm that the subject was at least 18 years old. The 
researcher observed the patient's registration process. The requirement that the patient speaks 
English was met if the patient completed registration independently, without the use of an 
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interpreter. If the patient responded appropriately to the researchers' conversational questions, 
the criterion that he/she is of sound mind was met. The researchers also observed the patients 
handle a writing implement during registration to rule out motor impairment. The researchers 
then asked all patients meeting the study entrance criteria for consent to participate in the 
research project. " 
In inpatient areas, the researchers queried the primary nurse to assure that the patient met 
the study criteria. Further, the patient's mental status and ability to handle a writing implement 
were assessed directly by the researcher at the time of data collection to assure the absence of 
transitory problems with cognition. 
Those patients giving consent then completed two copies of the informed consent form 
(See Appendix J), returned one copy to the staff and retained the second copy for their records. 
The researcher witnessed the consent, and answered any questions. If the researcher was not the 
principal investigator, and he/she could not resolve questions relative to the consent, the 
principal investigator was contacted. This happened only twice during the study period, in both 
cases the patients required reassurance that they would not be contacted in the future to provide 
more data. Completed consent letters were then placed in the consent letter file folder in a 
secured research file box. In order to conceal the patients' identities and protect privacy, signed 
consent letters were stored separately from the completed test materials 
Completion a/Tests by Participants. 
After the consent was obtained, the patient was given an envelope containing the 
research materials. The patient was asked to complete all portions of the testing materials, per 
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the instructions, and to return the completed forms in the sealed envelope to the researcher. The 
researcher remained in the clinical area to answer questions and assist the patients as necessary, 
but did not read materials for the subjects. Completed test packets, along with consent letters 
were retrieved by the principal investigator every Tuesday and data aggregated in SPSS version 
10.0 (2000). 
Participants and Demographic Data 
Subjects Lost to the Study. 
Of the 250 subjects who signed informed consent letters and took research packets, four 
subjects in radiation oncology left the area without returning the data and seven more (two in 
radiation oncology and five in the MPA) did not complete all requested tests. Because 
participation was blinded, nothing is known about those subjects who did not complete the 
testing. 
Participants' Demographic Data. 
A sample of 239 adults being treated for cancer in either outpatient or inpatient areas in 
a large community teaching hospital provided complete data. The complete demographic 
profile of the sample is described in Table 4. Of the sample 210 were outpatients, 19 were 
inpatients and 10 did not indicate their status. There were 146 females and 93 males. Eighty 
one percent of the subjects ranged in age from 44 years old to 79 years old. 
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The sample reported a variety of cancer diagnoses. The most frequently reported type of cancer 
was female breast cancer (11.2%), followed by prostate (5.7%), lung (4.1 %), colon/rectal 
(3.9%), ovarian (3.4%), lymphoma (1.8%), pancreatic (0.7%), stomach and kidney (each 0.2%) 
cancers. Six and eight-tenths percent of the sample reported other types of cancer diagnoses. 
Most subjects were being treated for a primary occurrence of the disease and were within a year 
of diagnosis. Most reported low level of, or no, pain associated with the diagnosis, and were 
treated with at least two types of medications in addition to the primary cancer treatment. The 
cancer treatment for the majority of the sample was chemotherapy (15.1 %). Radiation therapy 
alone (9.1 %) or combinations of treatments (l 0.1 %) were typical in the rest of the sample. 
Of the sample, 81 % was educated at the high school level or more, and 25% held 
graduate or technical degrees. The majority of the respondents earned between $10,000 per 
year and $50,000 per year and was disabled, unemployed by choice or retired at the time of the 
study. The average subject resided with his/her significant other. The subjects were 
predominately Caucasian. 
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Table 4 
Demographic Profile 
Percent of Percent of 
Variable t' Number Sample Variable Number Sample 
Admission Status Extent of Cancer 
Inpatient 19 7.9 Primary 
Outpatient 210 87.8 Occurrence 123 51.5 
Not Reported 10 4.1 Reccurrence 33 13.8 
Local Disease 19 7.9 
Metastatic Disease 38 15.9 
Not Reported 4 1.7 
Sex 
-
Female 146 6l.1 
Male 93 38.9 
Age Time Since the Current 
18-30 6 1.0 Diagnosis 
31-43 20 3.3 3 months or less 73 30.5 
44-55 56 9.1 3 months to 1 year 109 45.6 
56-67 68 11.1 More than I year 53 22.2 
68-79 71 11.6 Not Reported 4 1.7 
80-91 18 2.9 
Type of Cancer Education 
Breast 69 28.9 Some High School 20 8.4 
Prostate 35 14.6 High School 
Lung 25 10.5 Diploma 72 30.1 
Colon/Rectal 24 10.0 Some College 45 18.8 
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Percent of Percent of 
Variable Number Sample Variable Number Sample 
Ovarian 21 8.8 College Degree 38 15.9 
Lymphoma 11 4.6 Graduate Degree 29 12.1 
Pancreatic 4 1.7 Trade/technical 
Hodgkin's 
t' 
2 0.8 School 30 12.6 
Stomach I 0.4 Not Reported 5 2.1 
Kidney 1 0.4 
Other 42 17.6 
Not Reported 4 1.7 
Yearly Income Living Arrangement 
Less than $10,000 16 6.7 Lives Alone 44 18.4 
$10,001-25,000 60 25.1 Lives with Significant 
$25,001-50,000 57 23.8 Other 134 56.1 
$50,001-75,000 40 16.7 Lives with Significant 
$75,001-120,000 34 14.2 Other and 
More than $120,000 11 4.6 Dependent Children 28 11.7 
Not Reported 21 8.8 Lives with Parents 3 1.3 
Lives with Significant 
Other and Parents 4 1.7 
Other 20 8.4 
Not Reported 6 2.5 
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Percent of Percent of 
Variable Number Sample Variable Number Sample 
Current Treatment Current Medications 
Surgery 4 1.7 Pain 3 1.3 
" 
Chemotherapy 93 38.9 Nausea 13 5.4 
Radiation Therapy 56 23.4 Fatigue 
.., 1.3 .J 
Hormonal Therapy 2 0.8 Vitamins 19 7.9 
Surgery + Chemotherapy 4 1.7 Hormones 8 3.3 
Other 24 10.0 
Chemotherapy + 8.4 More than One 104 43.5 
Radiation Therapy 20 More than Three 14 5.8 
7.9 None 47 19.7 
Surgery + Chemotherapy 19 Not Reported 4 1.7 
+ Radiation Therapy 9.6 
7.5 
Other 23 
Not Reported 18 
Ethnicity Current Level of Pain 
Caucasian 210 87.8 0 125 52.3 
African-American 5 2.1 1 22 9.2 
Hispanic 4 1.7 2 21 8.8 
Other 2 0.8 3 18 7.5 
Not Reported 18 7.5 4 13 5.4 
5 6 2.5 
6 7 2.9 
7 6 2.5 
Validation Distress Thermometer 78 
8 3 1.3 
9 I 0.4 
Not Reported 17 7.1 
Employment 
40 Hours a Week or 
More 39 16.3 
21-39 Hours a Week 10 4.2 
20 Hours a Week or Less 15 6.3 
Unemployed by Choice 54 22.6 
Disabled 44 18.4 
Retired 53 22.2 
Not Reported 24 10.0 
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Distress Profile. 
The participants' reports of distress varied widely. Analysis revealed an even 
distribution of scores, ranging from zero (no distress) to 10 (the worst imaginable distress). The 
most frequently reported level of distress was zero (5.2%). The next most frequently reported 
distress score was 5.0 (4.1%). Table 5 summarizes the distress profile of the sample. The 
average level of distress in the sample was 4.268, with a standard deviation of 3.178. The cutoff 
score of 5, signifying moderate or clinically significant distress, was met or exceeded by 37.7% 
of the sample. 
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Table 5 
Distress Profile (n=239) 
Analogue Distress ]i'reguellcy ofthe *" , ,$" Cumulative; 
Score' Score Percent of the Sample Percentage 
, $ , 
O~O 
0.2 
0.3 
05 
4.5 
32 
2 
16 
14 
2 
11 
18 
2 
2 
12 
2 
13.4 
6.7 
0.4 
0.4 
5.9 
"0.8·. 
OA 
0.4 
0.4· 
7.5 
0.8. 
0.8 
0.2 
0.2 
0.8 
13.4 
14.2 
14.6 
21.3 
21.8 
22.2 
28.0 
28.9 
29.3 
29.7 
34.3 
34.7 
35.1 
42.7 
43.5 
44.4 
44.8 
49.8 
50.2 
50.6 
51.5 
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iXtnalogue Distress ~ ~ F~cq~ucncy~ot'tIle"" m ~ ¥" ~"t§umulative ' ~ 
Score Score' , Percent oHhe Sample, Percentage '.' 
5.0 25 
5 
10 
4 
17 
4 
12 
7 
10 
5 
9 
004. 51.9 
10,$ 
2.1 
1.7 
0.4 
0.4 
0.4 
2,9 
432 
2.1 
3.8 
62.3 
64.4 
64.9 
69.0 
69.5 
71.1 
71.5 
78.7 
79.1 
79.5 
81.2 
86.2 
86.6 
87.0 
90.0 
94.1 
96.2 
100.0 
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Frequency of Symptoms. 
The total number of problems reported had a significant relationship with the analogue 
distress score (! = .53, £ < .0001). The most frequently reported problem associated with 
distress in this sample was fatigue (51.6%) and the least frequently reported problems were 
trouble with child care and loss of faith (each 2.1 %). Table 6 presents a summary of the 
problems reported by the sample in order of descending frequency. The mean number of 
problems associated with distress ascribed to by the sample was 5.38, with a standard deviation 
of 4.97. The range was zero to 27. The total number of problems had a significant relationship 
to the total analogue distress score (! = .53, £ < .0001). 
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Table 6 
VaHable Number Positive Percent 
Fatigue 130 5l.6 
Worry 99 39.3 
Problems with Sleep 90 35.7 
75 2S>.8 
Depression 74 29.4 
Sadtless 63 - ·25.0 
Constipation/Diarrhea .. 63 25.0 
55 21.8 
Problem~D~alingwith Partner 53 2l.0 
51. ·20.2 
c . 
Changes i~ Bowel Functioning 46 18.3 
. 43 
Functioning 
Nausea 42 16.7 
Problems with Eating 41 16.3 
, '_ ... , .:2:: .. ' .. ':" .. -_. 
Problems with Work 37 15.2 
Problems Getting Around 34 13.5 
Problems Dealing with 32 12.7 
Children 
Changes in Skin 32 12.7 
Problems Breathing 31 12.3 
Problemswithlndigestton' 
Problems Relating to God 
Problems\"ith Hciusing 
changes in Urinary 
Functioning 
,Problems with Insurance 
Nasal Congestion 
Probl~ms with tra~sportation'· 
Problems with Sore Mouth 
'Fever 
. , 
Other Problems 
Problems with Child C~~e 
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·Percent 
"} I,J 
25 9.9 
24 9.5 
24 9.5 
23 9.1 
23 
23 
19 
18 
13 5.2 
10 4;0 
9 3.6 
5 2.1 
5 2.1 
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Results 
The reliability of the responses to DT items was evaluated using Chronbach's alpha. An 
alpha of at least .7 was required for confidence in the scale's reliability. Although Nunnally 
(1978) originally recommended that the alpha coefficient be .8 or .9 for basic research, modern 
researchers (Clark & Watson, 1998, pp.230) accept that an alpha coefficient of.6 or .7 is a good 
or adequate indicator of internal consistency. 
A factor solution was derived using Pearson-r correlation matrices of the 33 items on the 
Distress Thermometer for the sample (n = 239). A principal components factor analysis with 
varimax rotation was performed. Results were checked against the scree to verify data fit. The 
reliability of the factor solution was checked in two ways. First, a Pearson's product moment 
correlation matrix of each factor with the total distress score was constructed with a correlation 
of 2 < .01 considered significant. Second, each factor's reliability was confirmed using 
Chronbach's alpha. Because it is expected that lesser factors may identify a logical component 
of the concept, while not demonstrating the level of relationship among the items that initial 
factors demonstrate, a less rigorous standard of ~ = .5 was used for confidence in the factor's 
reliability. 
The correlations among the DT (Holland et aI., 2000) total score, reported as an integer 
ranging from zero to ten, the total score of the RSC (deHaes et aI., 1990), reported as an integer 
ranging from zero to four, the total score of the FLIC (Schipper et aI., 1983), reported as an 
integer ranging from zero to seven, and the OSI of the BSI (Derogatis, 1993) reported as an 
integer from zero to four were analyzed in a correlation matrix using the Pearson's product 
moment comparisons. Although the scores on the Distress Thermometer (Holland et aI., 2000) 
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are nonparametric data, authors (Aiken, 1996; Nunnally & Bernstein, 1992) suggest that 
Pearson's! is sufficiently robust to be used in non-interval applications. Correlations with a 
probability of2 < .01 were considered significant. 
The correlations between global severity index scores of the BSI (Derogatis, 1993) and 
the low medium and htgh total scores of the DT (Holland et aI., 2000) were further analyzed in 
three correlation matrixes. DT (Holland) scores of three and less were considered low, those 
between four and six were considered moderate, and those of more than seven were considered 
high. As before, the BSI (Derogatis) scores were reported as integers ranging from zero to 
four. The matrixes were analyzed for the significance of the relationship between the variables 
using Pearson's product moment correlations. Correlations with a probability of 2 < .01 were 
again considered significant. 
Reliability and Factor Structure. 
The internal consistency of the analogue distress thermometer scores was high (~= .86). 
Factor analyses were performed using the default options of the SPSS program version 10 
(2000). An II-factor solution was derived (See Table 8). Table 9 lists the individual items on 
the Distress Thermometer (Holland et aI., 2000) to the left, displays factor loadings of 0.4 or 
greater for each item and provides a summary of the item's communality. A comparison with 
the scree confirmed that an II-factor solution was a suitable model for the data. The 
reliabilities of the factors ranged from ~ = .74 (factor 1) to ~ = - .08 (factor 11). The reliability 
analysis is summarized in Table 7, and discussed below. Each factor with the exception of 
factor 11 was significantly correlated with the total distress score. Factor loadings were 
analyzed and factors named by a panel of three experts. 
Table 7 
Reliability of the Factor Solution 
Factor Name 
Negative Emotion 
Interpersonal/Social Problems 
Physical Symptoms/GI 
Treatment Side Effects 
Problems with Activities of Daily Living 
Physical symptoms/Neurologic 
Physical symptoms/Infection/Excretory 
Dryness/Epithelial Cell Changes 
Nausea 
Other 
Childcare 
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Chronbach's Alpha 
.7438 
.7379 
.6685 
.5507 
.6045 
.5274 
.5915 
.4730 
**.1118 
.4002 
**-.0832 
* *Factor exhibits insufficient reliability for interpretation 
Factor Analysis. 
Overall 63.3% of the sample variance is accounted for by the II-factor solution. (See 
Table 8) Examination of the factor loadings produced an interpretable factor pattern. 
Twenty-four of the 33 items had factor loadings of 0.4 or greater on only one factor. Nine items 
were not associated with a single factor as they had loadings of 0.4 or more on two or more 
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factors. These nine items included problems with work/school, bowel changes, problems with 
eating, insurance, transportation, mouth sores and difficulties with sleep, fatigue and sex. 
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Table 8 
Factor Structure: Analysis 
%of Cumulative 
Factor Eigenvalue Variance %of 
Variance 
Negative Emotion 6.186 18.744 18.744 
Interpersonal/Social Problems 2.349 7.117 25.861 
Physical Symptoms/GI 5.647 31.508 
Treatment Side Effects 1.654 5.012 36.520 
Problems with Activities of Daily Living 1.559 4.723 41.243 
Physical symptomslNeurologic 1.503 4.554 45.797 
Physical symptoms/Infection/Excretory 1.328 4.025 49.821 
Dryness/Epithelial Cell Changes 1.235 3.742 53.564 
Nausea 1.132 3.430 56.994 
Other 1.059 3.210 60.204 
Childcare 1.035 3.137 63.341 
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Table 9 
Items Loading on Each Factor 
Negative Social! Physical Treatment Activities of Physical Physical Dryness/ Nausea Other Childcare Com-
Emotion Inter- Symptoms/ Side Effects Daily Symptom! Symptoms Epithelial munity 
Personal Pain/GI Living Neuro Infection! Changes 
Excretory 
Item 
Sadness 0.8 0.629 
Worry 0.7 0.581 
Nervous 0.7 0.658 
Depressed 0.6 0.652 
Relating to 0.8 0.710 
God 
Housing 0.8 0.724 
Dealing 0.5 0.581 
children 
Work 0.5 0.4 0.578 
Dealing 0.4 0.572 
Partner 
I 
Negative Social! Physical Treatment Activities of Physical Physical Dryness/ Nausea Other Childcare Com-
Emotion Inter- Symptoms/ Side Effects Daily Symptom/ Symptoms Epithelial munity 
Personal Pain/GI Living Neuro Infection/ Changes 
Excretory 
Constipat- 0.7 0.545 
ion/ 
Diarrhea 
Indigest- 0.6 0.562 
Ion 
Bowel 0.6 0.4 0.599 
Changes 
I 
Pain 0.5 0.570 
i 
Eating 0.4 0.5 0.588 
Insurance 0.4 -0.5 0.627 
Loss of 0.7 0.675 
Faith 
Swelling 0.7 0.596 
Mouth 0.6 0.4 0.728 
Sores 
Getting 0.7 0.652 
Around 
Negative Social! Physical Treatment Activities of Physical Physical Dryness/ Nausea Other Childcare Com-
I 
Emotion lnter- Symptoms/ Side Effects Daily Symptom/ Symptoms Epithelial munity 
Personal Pain/GI Living Neuro Infection! Changes 
Excretory 
Bathing 0.5 0.532 
Dressing 
Breathing -0.4 0.703 
Transport 0.5 -0.5 0.650 
I 
I 
Tingling 0.7 0.679 
I 
Hand/foot ! 
Sleep 0.5 0.4 0.638 
Childcare 0.8 0.740 
Other 0.8 0.656 
Nausea 0.7 0.681 
Fatigue 0.4 0.4 0.558 
Changes in 0.7 0.666 
Urination 
Fever 0.6 0.616 
Skin 0.8 0.663 
Dry/Itchy 
Nose Dry/ 0.6 0.651 
- - -
L------. .... _~ ____ ._ 
'------- ---
Negative Social/ Physical Treatment Activities of Physical Physical Dryness/ Nausea Other Childcare Com-
Emotion Inter- Symptoms/ Side Effects Daily Symptom/ Symptoms Epithelial munity 
Personal Pain/GI Living Neuro Infection/ Changes 
Excretory 
Congested ! 
Problems 0.4 0.4 0.4 0.642 
with Sex 
-'----- - '--------- "------ -- -
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Four items loaded most heavily on the Factor 1: sadness, worry, depression, and 
nervousness. Items concerning trouble dealing with one's partner and fatigue, both 
symptomatic of affective dysfunction (DSM-IV, 2000) were also associated with this factor. 
These items appear to refer to negative mood or affective issues. The factor accounted for 
18.75% of the commonivariance and was called "Negative Emotions". It exhibited robust 
reliability (~= .74). 
Five items loaded on Factor 2. They were problems relating to God, problems with 
housing, difficulties relating to partner, difficulties relating to children and problems with work. 
Sexual issues were also associated with this factor. If housing issues were related to the 
inability to exercise the interpersonal skill set necessary to find and keep a job, as they generally 
are (Hall, 1999), the common factor in these items is failure of relationships. The factor 
accounted for 7.1 % of the sample variance and was named "Interpersonal/Social Problems"; the 
factor was highly reliable (~= .74). 
The third factor accounts for 5.65% of the common variance and was composed of four 
items that describe gastrointestinal symptoms and pain. The items were constipation or 
diarrhea, indigestion, changes in bowel patterns, and pain. Problems with eating and with sex 
also loaded on this factor. These gastrointestinal problems are common side effects of many 
chemotherapy agents (Valley & Balmer, 1999), and of opiod pain medications (BaummID, 
1999). The factor was referred to as "Physical Symptoms/GIIPain". It exhibited good 
reliability in this sample (~ = .67). 
The three items that loaded on the fourth factor were loss of faith, feeling swollen and 
mouth sores. The factor accounted for 5.01 % of the variance. These problems are common 
effects of both radiation therapy (Laszlo et aI., 2001) and certain adjunctive medications and 
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chemotherapy (Chabner, 1982). The factor was named "Treatment Side Effects". Its reliability 
coefficient was acceptable (~ = .55). 
Factor 5 accounted for 4.72% of the common variance. Three items trouble with 
bathing and dressing, problems getting around and difficulties with transportation loaded on this 
factor. Trouble with ea'ting was also associated with the factor. The problems described were 
inability to accomplish usual activities necessary for daily living and deterioration in quality of 
life that often results from cancer and its treatments (Schag et al., 1991). The factor was dubbed 
"Activities of Daily Living (ADL)" and performed well in terms ofreliability (~= .60). 
The items loading on the sixth factor were trouble with tingling in the hands or feet and 
difficulties with fatigue and sleeping. The factor accounted for 4.55% of the variance. The 
problems are associated with neuropathies and neurological issues (Rubin, Kimmel & Cascino, 
1998; Wang & Schroder, 1998) and the factor was called "Physical ProblemslNeurologic". It 
achieved an alpha level of .53. 
Factor 7 was composed of changes in urination and bowel function, sexual problems and 
fevers. It accounts for 4.02% of the sample variance and was called "Physical 
Symptoms/Infection/Excretory Problems". Confidence in its reliability was adequate, a = .59. 
Items that loaded on the 8th factor were problems with dry/itchy skin and a 
dry/congested nose. Mouth sores were also associated with this factor. It accounted for 3.74% 
of the common variance. These problems all result from the destruction of rapidly mUltiplying 
epithelial tissues, and the factor was named "Dryness/Epithelial Changes". The alpha 
coefficient for Factor 8 was a = .47. 
Factor 9 was inversely correlated with insurance and transportation and directly 
correlated with nausea and accounted for 3.43% of the common variance. The reliability 
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coefficient for this item failed to meet the threshold for confidence a = .11. No interpretation of 
this factor was possible. 
Other problems, trouble sleeping and problems with work loaded on Factor 10. Factor 
10 accounted for 3.21 % of the variance. It was not possible to ascertain what respondents 
c' 
meant by "other problems", and the factor's reliability fails to meet the desired thresholp (a = 
0.40). Like Factor 9, Factor 10 was uninterpretable. 
Factor 11 accounted for 3.13 % of the variance. It represented only five cases and was 
not significantly related to the total distress score (! = .531,2 < .025). The reliability coefficient 
was likewise unacceptable (~ = - .08). Probably due to the small number of respondents 
reporting child-care issues, this factor was not sufficiently reliable for confidence in its 
interpretation. 
Convergent Validity. 
The total DT (Holland et al., 2000) scores were directly correlated with the Global 
Severity Index (GSI) of the BSI (Derogatis, 1993) (! = .496,2- < .0001), the total score of the 
RSC (deHaes, vanKnippenberg & Neijt, 1990) (!:,.= .505, 2-< .0001), and the total score of the 
FLIC (Schipper et al., 1984) (!:,. = .641, 2-< .0001). 
Sensitivity. 
Low DT (Holland et al., 2000) scores (0-3) displayed an inverse relationship (r = -.445, 
2-< .0001) with BSI GSI (Derogatis, 1993) scores, moderate DT scores (4-6) demonstrated no 
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relationship (! = - .078,2 = 0.232) with BSI GSI scores, and high DT scores (7-10) a 
significantly positive relationship (! = .399, 2-< .0001) with BSI GSI scores. 
Discussion 
Cancer, its symptoms and the side effects of its treatments cause biopsychosocial 
distress. As cancer survivorship and chronicity increases (ACS, 2001), interest in the 
identification and treatment of distress in the medical community also increases (Holland et ai., 
2000). Researchers (Bruera et ai., 1991; Chang et al., 1997; deHaes et al., 1990; Holmes, 1991; 
Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Coyle et ai., 1994; Rhodes et 
al., 2000) developed useful paper and pencil distress self-assessments in the 1980s. The time 
required administering and scoring these tests made them undesirable for general screening in 
large cancer populations. Within the limitations of this study, The NCCN Distress 
Thermometer (DT, Holland et al., 2000), a brief, easily administered measure, appears to be a 
conceptually sound, sensitive, reasonably internally consistent measure for distress screening 
that performs in a valid manner. 
The participants in this study were both similar tpo and different than the normative 
national population. In its Cancer Facts and Figures (2001), the American Cancer Society 
reported that 80% of cancers are diagnosed in middle age and the participants in this study are 
most typically middle aged, so the age of the sample is typical for cancer patients in America. 
The distribution of cancer diagnoses in the sample also mirrors current reports of the 
distribution of specific cancers in the American population (ACS, 2001) except that cases of 
Hodgkin's lymphoma are underrepresented in this sample. It is not clear why Hodgkin's 
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Disease is underrepresented as the cancer center where the study was conducted treats this 
illness. The symptoms of, and side effects of treatments for, Hodgkin's Disease include fatigue, 
difficulty breathing and burns to the skin (Holland et al., 1998). These problems may be less 
prevalent in the sample than expected. A factor that captures a like symptom profile might have 
been identified in a §ample that included a normative number of patients with Hodgkin's 
Disease. 
The sample is unlike the national cancer population in at least two ways. First, the 
overall gender distribution in the cancer population in the United States last year was reported to 
be 51% male and 49% female (ACS, 2001). The sample in this study is predominately female. 
The presence of regional gynecologic oncology and breast health centers at the site of data 
collection account for this disparity between the gender profile of the sample and of the cancer 
population as a whole. Women typically report more distress than men, especially distress 
associated with pain (Bredart et al., 1999; Zigmond & Snaith, 1983). Therefore, it is possible 
that the feminine nature of the study sample inflated the mean measure of distress and the 
number of problems reported. The lack of non-Caucasian representation in the study sample is 
attributable to the geographic location of the cancer center in a largely Caucasian suburb in 
Pennsylvania. A recent health survey of the same area found that the non-Caucasian population 
was 4% (Behavioral Health Risks of Lehigh Valley Adults, 1998), so the study sample 
represents the local popUlation. Distress descriptions have also been shown to vary with 
ethnicity (Faller et al., 1999; Hurny et al., 1993), although the differences between Caucasian 
and non-Caucasian distress descriptions have not been studied. 
Other issues of note are that there are few participants who are less than 30 years of age 
included in the sample and that the majority of the participants had a localized cancer that was 
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diagnosed in the last year, as opposed to chronic metastatic disease. The duration and severity 
of the disease have been reported to be directly related to the severity of distress and the number 
of cancer related problems reported (Akechi et aI., 2000; Bredart et aI., 1999; Tope et aI., 1993). 
Patients with localized disease, relatively early in cancer treatment, are expected to have fewer 
and less severe problerlls on average than those with metastatic disease in treatment for 
prolonged periods oftime. This observation again points to the premise the levels of distress 
and numbers of problems reported herein may underestimate those levels in the general 
population. 
The data support the premise (Holland et aI., 2000) that distress is a highly variable 
phenomenon that results from failure to cope with a highly variable number of problems. 
Similar variability was found by Holmes (1991) using the Symptom Distress Scale (McCorkle 
& Young, 1978) in samples of radiation therapy and chemotherapy patients. The Mean distress 
scores reported were 710.4 + 152.8 and 746.5 + 150.6 respectively. Likewise in Portenoy, 
- -
Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Coyle and colleagues' (1994) study of 
the properties of Memorial Symptom Assessment Scale in an outpatient cancer population, the 
mean number of symptoms reported was 9.7 with a variability of ± 6.0. High variability, both 
in terms of standard deviations from the total distress mean and the number of problems 
identified by subjects, is expected given the dynamic nature of cancer and its treatments, and the 
transience, and complexity of associated symptoms. Disparities in total number of symptoms 
may be related to the nature of the sample. For example Porteny's sample was predominately 
inpatient colon/rectal cancer patients, while the sample in this study was predominately 
outpatient breast cancer patients. The mean level of distress and numbers of numbers problems 
associated with that mean are predictably higher in inpatients that typically have either more 
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advanced disease or more debuilitating treatments, than for outpatients who are typically less 
fragile. The relatively low level of distress and conservative numbers of problems found in this 
sample may further be explained by observing that it does not include patients who are being 
treated with physically incapacitating interventions like stem call transplants and abolition 
interventions for leukemia. Regardless of the differences in patterns of central tendency, the 
finding of large variability of both the level of distress, and the number of problems associated 
with it, holds across differing samples and measurement devices. 
The prevalence of clinically significant distress, or DT analogue scores of five or more 
(37% of the sample), reported by the sample mirrors the prevalence of psychiatric symptoms in 
cancer popUlations found in other some studies (Bredart et aI., 1999; Ford, Lewis & Fallowfield, 
1995). A previously conducted study (Roth et aI., 1998) suggests that two-thirds of those 
identified as significantly distressed through screening with the DT (Holland et aI., 2000) would 
subsequently be diagnosed with affective or other psychiatric disorders at a second level 
assessment. Although, second level assessment was not done in this study, 86% or 207 of the 
239 respondents, reported some distress, 38% or 91, of the respondents' distress scores were 
less than five, the cutoff score for significant distress. This finding has two implications. First, 
all reported distress may be significant from a quality of life point of view and should be 
evaluated through follow-up assessment. Second, more than 38% of this sample reported 
subsyndromal distress that would certainly be missed using tests for psychiatric symptoms. 
Interventions aimed at preventing emotional decompensation are most effective in these 
distressed, but not emotionally ill, patients. 
The internal consistency of the thermometer (Chronbach's Alpha (CA)= 0.87) in this 
sample is equivalent to the reliability of other longer distress measures. For example, the CA 
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for symptom distress using the Adapted Symptom Distress Scale-2 (Rhodes et aI., 2000) in a 
sample of 175 oncology patients was 0.76. It was 0.88 for the Memorial Symptom Assessment 
Scale (Portenoy, Thaler, Komblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et aI, 1994) in a 
sample of 297 cancer patients. In this study, there is reasonable confidence that the DT 
(Holland et aI., 2000) measures distress as its primary concept. 
Eight reliable factors were identified. These factors fall into the same general domains 
of emotional, interpersonal, physical, and practical problems as other measures of distress 
(Bruera et aI., 1991; Chang et aI., 1997; deHaes et aI., 1990; Holmes, 1991; Portenoy, Thaler, 
Komblith, McCarthy-Lepore, Friedlander-Klar, Coyle et aI., 1994; Rhodes et aI., 2000). Table 
10 compares the factor structures of the five distress scales previously reviewed with the factor 
structure of the DT in this sample population. 
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Table 10 
Comparison of Factor Structure Across Distress Measures 
EMOT SOC ADL PHY 1 
FLIC X X X X 
ASDS-2* X X 
RSC X X X 
MSAS** X X 
MSAS-SF X X 
DT X X X X 
Emot = Negative Emotions 
Soc = Socialiinterpersonal Problems 
ADL = Problems with Activities of Daily Living 
Phy 1 = One dimension of physical symptoms 
Phy 2 = Second dimension of physical symptoms 
Phy 3 = Third dimension of physical symptoms 
Phy 4 = Fourth dimension of physical symptoms 
Phy 5 = Fifth dimension of physical symptoms 
PHY2 
X 
X 
X 
PHY3 PHY4 PHY5 
X X X 
X X X 
* ASDS-2: GI problems, pain/discomfort, respiratory problems, fatigue/restlessness, 
concentration, *body image 
* * MSAS high and low frequency physical symptoms 
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All of the scales have at least two major sub-scales, emotional and physical 
symptomatology. Some scales do not have interpersonal items while others omit changes in 
ability to manage activities of daily living (practical problems). Early work (McCorkle & 
Young, 1978) demonstrated that a valid measurement of global distress requires only a 
unidimensional meAsurement of a small group of prevalent psychological and physical 
symptoms. So, distress measurement may be valid without interpersonal and practical 
subscales, and the major disparity among factors identified in each distress measure that 
remains is the number and composition of physical symptom subscales derived. 
The difference among physical symptom subscales found in distress measurement tools 
results both from differing experts' opinions about common physical symptoms found in the 
general cancer population and the nature of the validation samples. Cancer can affect every 
organ system and every human physiologic activity (Holland, 1997). Consequently, the list of 
possible physical symptoms in a general cancer population can never be complete. This point is 
easily illustrated. Many hematological cancers produce petechiae, or rash-like clusters of small 
blood filled lesions, on the skin (Patrick, Woods, Craven, Rokosky, & Bruno, 1986, p.262); 
none of the previously reviewed symptom checklists include problems with rashes. Also, 
women experiencing premature menopause common in many chemotherapy treatments often 
experience cold sweats. None of the reviewed symptom checklists offer "cold sweats" as a 
potential response. The symptom list is potentially endless. Table 11 compares the symptoms 
on five scales previously reviewed with those included in the DT (Holland et al., 2000). The 
DT is one of two instruments that included an "other" symptoms category. Although only 9 of 
the 243 subjects in this sample responded in the affirmative to the "other" category, the 
response set was identified as a sub-scale of the instrument, Factor 10. The inclusion of the 
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'other" category on the DT screening tool allows for a limitless list of problems that are not 
specified on the checklist to be reported. The nature of these problems can be detailed in an 
interview and appropriate clinical follow-up can occur. 
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Table 11 
Comparison of Physical Symptoms Across Distress Measures 
DT FLIC RSC MSAS ASDS-2 
Other X X 
Pain X X X X X 
Stomachache X 
No Appetite X X 
Nausea X X X X 
Fatigue X X X X 
Sleep X X X X 
Coughing X X 
Breathing X X X 
Mouth Sores X X 
Eating X 
Indigestion X X 
Constipation X X X X 
Diarrhea X X X X 
Bowel Changes X 
Urinary Problems X X 
Sweats X 
Fevers X 
Dry Skin X X 
Itchy Skin X X 
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DT FLIC RSC MSAS ASDS-2 
Dry Nose X 
Dry Mouth X X 
Swallowing X X 
Congested Nose /i X 
Shivering X 
Tingling Hands/Feet X X X 
Edema X X 
Sexual Dysfunction X X 
Sore Muscles X X 
Vomiting X X 
Dizziness X X 
Weight Loss X 
Hair Loss X X 
Burning Eyes X 
Bloated X 
The first two factors underlying the construct of distress in the DT (Holland et ai., 2000) 
reported by study respondents, negative emotion and interpersonal problems account for 25% of 
the response variance. These factors are also predominate sub-scales in longer distress 
measures (Bruera et aI., 1991; Chang et aI., 1997; deHaes et aI., 1990; Portenoy, Thaler, 
Kornblith, McCarthy-Lepore, Friedlander-Klar, Coyle, 1994) confirming the role of 
psychological issues in cancer distress. In this sample, the items loading on both factors were 
exceptionally consistent. The items that compose Factor 1, sadness, worry, nervousness, and 
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depression are all common labels for and fatigue, and marital dysfunction symptomatic of 
affective difficulty (DSM IV, 1994). In Factor 2, trouble dealing with partner, and children 
clearly signify interpersonal problems. Problems relating to God also loaded onto Factor 2. If 
God is conceptualized as an anthropomorphic being, the interface between God and human 
being becomes a relationship between mortal being and superhuman being. As with any 
human-to-human relationship, interpersonal problems in the human-to-God relationship exit. 
Anger, lack of trust in, and confusion about the relational rules occur in times of crises or 
profound change (Bowen, 1978). The remaining two items in the sub-scale, trouble with work 
and housing, are also associated with interpersonal difficulties. Inability to negotiate 
relationships has be found to be associated with to, or is co-existent with, difficulty in obtaining 
or maintaining employment (Hall, 1999). Under employment leads to and maintains difficulties 
with housing. It appears that there may be two major expressions of affective distress in this 
population: one experienced as ego dystonic or mood destabilizing symptoms and the other 
experienced as disruption in relational systems. 
Changes in functional status or ability to conduct activities of daily living result from the 
increasing fatigue and general debilitation that is pandemic in cancer populations (Patrick et aI., 
1986). This sub-scale is conceptually consistent with the concept of distress. Its inclusion on 
the DT (Holland et aI., 2000) makes it a more inclusive measure than some other less 
parsimonious measures (Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, 
Coyle, 1994). It appears that while debilitation is related to distress, the debilitated population 
in this sample is not the same as the emotionally upset population. A faction of the population 
was debilitated and not emotionally destabilized. This finding disagrees with the work that 
finds that emotional symptomatology increases as physical functioning decreases (Bredart et aI., 
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1999; Craig & Abeloff, 1974; Valente et al., 1994), but agrees with studies that find that the 
level of distress is influenced by both emotional and physical problems (Passik et al., 1995; 
Portenoy, Thaler, Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et al., 1994). The 
variables of emotional dysfunction and disability appear to be orthogonal subscales of distress 
in this sample. A line!r relationship between functional symptoms and emotional symptoms 
might have emerged if the study sample included a balanced number of inpatients who are 
likely to be more physically disabled than outpatients and those considered terminal by medical 
standards. Terminal patients usually are no longer in active treatment (although they may 
receive interventions for symptom management). This group of patients is the most severely 
functionally disabled. A relationship between declining functional status and increasing distress 
may be found in terminally ill patients but not in outpatients in active treatment. 
The DT (Holland et al., 2000) appears to describe the characteristics of a variety of 
physical symptoms in this sample. Of these symptoms, there is growing evidence that those 
associated with Factor 3; - pain, constipation or diarrhea (one item on the DT), bowel changes, 
and trouble with eating - constitute a sub-scale of physical problems that transcend the 
particular cancer diagnosis. The PainiGI symptoms factor found in this study equivalent to the 
"high prevalence physical symptoms factor" of the MSAS (Portenoy, Thaler, Kornblith, 
McCarthy-Lepore, Friedlander-Klar, Kiyasu et al., 1994), the FUC's Factor 5 (Morrow, Lindke 
& Black, 1992) and the ASDFS's Factors 1 and 2 (Rhodes et al., 2000). Portenoyand 
associates conclude that this factor has two subgroups, one related to pain and its treatment and 
the other to gastrointestinal symptoms. They may have reached this conclusion because of the 
large number of colon/rectal cancer patients in their sample. It is also plausible that this factor 
identifies symptoms that result primarily from pain and its treatments. The most usual treatment 
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for cancer pain involves a combination of nonsteriodal anti-inflammatory and opiate narcotics 
(Baumann, 1999). Both classes of drugs have gastrointestinal side effects. The most notable 
are the constipation and bowel problems that are persistent with the use of opiates (Baumann). 
Due to slowed peristalsis, constipation is also associated with anorexia and indigestion; thus, 
difficulty eating also';occurs. (Problems with eating and indigestion also load on this factor). 
Pain is often comorbid with cancer progression and intensification of treatment. The longer the 
course of the cancer treatment and the bigger the demand for ongoing health care, the more 
likely that insurance coverage will become problematic. Therefore, the correlation between 
insurance problems and pain, found in Factor 3, may be a secondary effect of chronicity. Of 
this study's sample population, 33% reported problems with pain. Participants reported that 
pain was second only to fatigue among distressing physical symptoms. Likewise, Factor 3 
accounted for more of the sample variance than any other group of physical symptoms. This 
finding concurs with the large body of literature that suggests that pain is a primary determinant 
of cancer distress (Koopman, Hermanson, Diamond, Angell, & Spiegel, 1998; McClement, 
Woodgate, & Degner, 1997; Payne et aI., 1998; Turk et aI., 1998; Zimmerman, Story, Gaston-
Johansson, & Rowles, 1999) and suggests that a pain sub-scale has been identified among the 
factors in this and other studies. 
The remaining factors, Physical SymptomslNeurologic, Fever/Excretory Symptoms and 
Dryness/Epithelial changes are similar to the group of low prevalence physical symptoms that 
compose sub-scale three of the MSAS (Portenoy, Thaler, Kornblith, McCarthy-Lepore, 
Friedlander-Klar, Kiyasu et aI, 1994). Heterogeneous samples can be expected to obscure 
disease specific differences in symptom clusters or sub-scales. Infrequently occurring problems 
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may form sub-scales that are disease specific. Therefore, secondary screening is necessary in 
the general cancer population to clarify the significance of symptom clusters. 
In this study, Factor 6, Physical Symptoms/Neurologic Changes, suggests that central 
neurologic disruption leading to insomnia and consequent fatigue and peripheral neuropathies 
represent one sub-sdHe of distress. The explanation for this may be that the neuropathic 
symptoms in this sample are sufficient to interfere with normal sleep patterns and lead to 
fatigue. The complaints of insomnia and fatigue are commonly heard in the chemotherapy 
treatment area, where the data were gathered. Alternatively, fatigue, sleep difficulties and 
neuropathies are side effects or certain classes of chemotherapeutic agents especially taxanes 
(Hall, 1999; Seidman et aI., 1995). This factor may be identifying these side effects. In a larger 
sample, this Factor 6 may emerge as two sub-factors. 
The physical problems associated with Factor 7 fever, bowel changes, problems with 
urination and sexual problems represent a group of low prevalence symptoms (Portenoy, Thaler, 
Kornblith, McCarthy-Lepore, Friedlander-Klar, Kiyasu et aI., 1994) that may be related in at 
least two highly speculative ways. These symptoms are known side effects of radiation 
treatments to the lower abdomen (Nickelson et aI., 1976; Patrick et aI., 1986). The factor may 
be identifying side effects of radiation. Alternatively, both bowel and urinary changes may 
result from infections. Diarrhea is symptomatic of intestinal infection and urinary burning 
symptomatic of urinary tract infections. Fever is a general systemic response to infection and 
sexual interest is likely to wane during acute symptomatic periods (Patrick). So, the factor may 
be identifing infection. 
The final group of low prevalence symptoms identified in sub scale 9, problems with the 
skin, nose and mouth sores are all physical changes that result from the destruction of rapidly 
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growing epithelial cells that form the surface of the skin and the linings of the nose and mouth. 
The lack of specificity of cancer treatments, especially chemotherapy, for cancer cells and their 
proclivity to destroy all rapidly dividing cells leads to the identification of this symptom cluster 
in the sample. 
Nausea, oftel1 thought to be a very prevalent problem in the cancer population, loaded as 
a single symptom on a factor that lacks reliability in this sample. Schipper and colleagues 
(1984) also found a serendipity factor of nausea alone when testing properties of the fourth 
generation FLIC in a sample of patients with mixed cancer diagnoses. Logically, nausea was 
expected to load on the PainiGI Symptoms factor. It is possible that adding more symptoms 
like vomiting and lack of appetite to the DT (Holland et aI., 2000) would result in the 
identification of a nausea sub-scale unrelated to other sub-scales. 
The final eight-factor solution accounts for 53.56% of the sample variance. We know 
that approximately 3% (Derogatis et aI., 1983) of the cancer population has personality 
disorders, about 12% have major depressive disorders (Akechi et aI., 2000; Chochinov et aI., 
1994) and although there is no research to report the actual prevalence, we can assume that a 
percentage have comorbid addictions. Although these problems certainly produce distress, they 
are not identified by the DT (Holland et aI., 2000). Additionally, unaccounted for variance may 
be related to other factors known to influence distress in cancer patients than are not accounted 
for by the scale. These include attitudinal factors (Lloyd, 1979; Weisman & Worden, 1976-77), 
intrusive thoughts (Baider & Denour, 1997), and degree of self monitoring (Schwartz et aI., 
1995) 
The convergent validity of the DT (Holland et aI., 2000) with the three other measures of 
distress is excellent in this sample. The total score of the DT is highly correlated with the total 
Validation Distress Thermometer 112 
distress scores (P < .0001) of the FLIC (Schipper et aI.,1984; r = .641), the RSC (deHaes et aI., 
1990; ~ = .505) and the Global Severity Index (GSI) of the BSI (Derogatis, 1993;!:.. = .496). The 
items in the FLIC focus on the dimensions of well being or the ability to manage one's life in 
the presence of physical symptoms and the interpersonal and emotional dimensions of the 
illness. The RSC fotuses on a group of high prevalence physical symptoms and the emotional 
distress dimensions. The highly significant correlations confirm that the DT adequately 
identifies distress associated with emotional, interpersonal, functional and highly prevalent 
physical symptoms. The BSI measures psychiatric symptoms. As expected, the DT total 
distress score is also highly correlated with the GSI, a valid measurement of the distress 
associated with emotional symptoms, of the BSI. However, it is the least perfect of the 
correlations. This leads to an exploration of the differences between the distress score and the 
GSI score. 
It is true that cancer populations with psychiatric symptoms are distressed (Akechi et aI, 
2000; Baider & DeNour, 1997; Bredart et aI., 1999; Derogatis et aI., 1979; Farber et aI., 1983; 
Mahon & Casperson, 1995; Massie & Holland, 1990; Shekelle et aI., 1981), however many 
distressed cancer patients may not report symptoms that indicate a psychiatric diagnosis (Craig 
& Abeloff, 1974; Faller et aI., 1999; Finlay & Dunlop, 1994; Ford et aI., 1995; Jarrett, Ramirez, 
Richards & Weinman, 1992; Lloyd, 1979; Rogertine et aI., 1979; Zabora et aI., 1997). If the 
DT (Holland et aI., 2000) score is a sensitive measure of distress in the sample, it should 
discriminate among portions of the sample with psychiatric illness and portions with 
subsyndromal distress, or distress that does not fit the profile of a diagnosable psychiatric 
illness. To examine this premise, the DT scores were divided into low (0-3), moderate (4-6), 
and high (7-10) ranges. The subsyndromal population should have a profile of moderate 
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distress score and with no relationship to the GSI (Derogatis, 1993) that is used to diagnose 
psychiatric illness. In other words this cohort of patients should report distress that fails to meet 
the threshold for psychiatric diagnosis. That relationship is exactly what was discovered. In this 
study, subjects who scored low on the DT scored higher on the BSI GSI (~= - .445,2 < .0001). 
Either this cohort udder reports its level of distress, or it denies the seriousness of its emotional 
symptoms. A second cohort reported scores that meet or exceeded the DT cutoff for clinically 
significant moderate distress, which were unrelated to the GSI scores for the same patients (~ = -
.078, 2 = .232). While this group reported distress, the level was not diagnostic of psychiatric 
illness. So the DT was sensitive enough to detect the subsyndromal distress found in the sample. 
It is hoped that identification of distressed but not psychiatrically ill patients will lead to 
interventions that prevent morbidity from emotional decompensation (NCCN, 2000). The third 
sample cohort reported both high DT and high GSI scores (~= .399,2 < .0001). This group of 
patients was both distressed and psychiatrically ill. 
The DT (Holland et ai., 2000) was easy to administer and score. The majority of this 
sample was educated at the high school level. The reading level appears to be simple enough 
for this cohort and those with more advanced education. The use of ordinary language, instead 
of technical names for symptoms (e.g. "tingling in the hands and feet" instead of peripheral 
neuropathy), lends to its interpretability. The level of education at which the tool becomes too 
difficult to use is not known, although illiterate patients would need assistance in responding to 
items. No subjects objected to its format or content. The gradation in tenths between the 
integers actually allowed for 100 discriminations among distress levels and the scoring was 
clear and easy. One administrative issue was discovered. In a small percentage of the cases, 
patients ascribed a level of distress ranging from zero to ten to each problem. This added to the 
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response burden. The information given, however, might be useful in prioritizing referrals and 
beginning problem resolution addressing the most troublesome problems first. Addition of a 
simple line of direction to the tool would standardize the response pattern. In further 
development, the tool might be trial using either a yes/no response or an integer response format 
and its performance ~nalyzed using both response sets. 
Limitations of the Study 
Although the results of this study are a first step toward confirming the validity of the 
DT (Holland et aI., 2000) as a brief, efficient screening tool for distress in cancer populations, 
the study has many limitations. The sample is one of convenience, comprised of patients from 
one regional medical center in northeastern Pennsylvania. The population is largely Caucasian. 
It is not known how the scale would perform in a more ethnically diverse population. All 
members of the sample in this study are in active treatment with either chemotherapy or 
radiotherapy. The scale may perform differently and its factor structure may vary if it were 
administered in cohorts of terminal patients, those who have active disease but are receiving no 
medical treatment aside from symptom management, or newly diagnosed patients before 
treatment. Since the DT is designed as a general screening tool, there was no attempt to limit 
the sample to one cancer diagnosis. It is probable that the instrument performs differently in 
special cancer populations and that its factor structure, especially physical symptom factors, 
would vary. This might be especially true of tumors that produce endocrine hormones and 
those with central nervous system tumors or brain metastasis. 
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The unusual gender make up of the sample undermines confidence in the description of 
the level of distress and the problem distribution. We might expect a largely female population 
to report more distress and a greater number of problems than a gender-balanced population at 
the same stage of the disease. 
The adjunctiVe medication profile of the sample was not analyzed in detail, however the 
most frequently reported combination of adjunctive medications was vitamins/supplements and 
pain medications. Therefore, a much larger percentage of the sample used pain medications 
than indicated in the "pain medication" category of the demographic data. This data is not 
sufficient in detail to lead to conclusions about the relationships among medications and reports 
of distress. It is likely that this is a complex relationship, as many medications both decrease 
and increase distress. For example: antibiotics may decrease fever and other signs of infection 
while increasing nausea and gastrointestinal symptoms. 
No cancer patients treated with surgery alone are included in the sample. The tool does 
not include problems with body image, loss of strength and loss of functions that are typically 
associated with surgery. It appears that the tool's performance in a surgical cancer population 
would differ from its performance in the study sample. 
Last, very little can be understood about how the DT performs in inpatients as the 
sample was overwhelmingly outpatient in nature. No assumptions about its validity in 
inpatients can be made. 
Due to the cross-sectional design, no inferential conclusions can be drawn about the 
relationships among stage of disease and the distress score, or about the stability of the 
measurement of distress in the population. 
Validation Distress Thermometer 116 
Recommendations for Future Research 
Since the purpose of the DT is screening, it is less imp0l1ant to ask about its internal 
structure, that it is to inquire about its utility as a screening devise. However, as a brief pain 
measurement has clinical utility, the validation of Factor 3 with valid pain scales should be 
undertaken. The nature of Factor 6 might be clarified by testing the instrument's performance 
in a sample of radiation therapy clients and controlling for the physical location of the treatment 
area. Future studies should also concentrate on establishing its concurrent validity in gender 
neutral outpatients, inpatients and ethnically diverse populations. 
More importantly, work like Roth and colleagues (1998) should continue on the use of 
secondary assessments in areas of distress identified by the screening tool. This will contribute 
to the tool's clinical utility. 
Another area, not previously discussed, is the health care staff s reaction to the idea of 
distress screening. The study met resistance as nurses were worried that asking patients about 
their distress would upset them. Some nurses wanted the term "stress" substituted for the term 
"distress" believing that it is more a more acceptable descriptor of emotional content than 
distress. Others wanted the scale changed from zero to ten to zero to five, while retaining five 
as the threshold for significant distress. Research that identifies the sources of resistance to 
distress screening, and trials interventions to reduce this resistance, should be conducted. 
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Conclusions 
The Distress Thermometer is a reasonably sensitive, reliable and valid screening tool for 
distress in outpatient general cancer patients. It meets all of the agreed upon criteria (Barg et 
aI., 1994; Finlay & P,unlop, 1994; Grant et aI., 1990) for self-repOlis of distress in cancer 
populations. Its wider use will contribute significantly to proper identification of distress in 
large cancer populations. 
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Appendix A 
The Distress Thermometer 
Distress Management PRACTICE GUIDELINES VERSION 1.2000 
During the past week, how 
distressed have you been? 
Extreme distress 
No distress 
From Holland et al., 2000, p. DIS 25 
Please indicate your level of distress on the 
thermometer and check the causes of your distress. 
Practical problems 
-Housing 
-Insurance 
- Work/school 
- Transportation 
- Child care 
Family problems 
- Dealing with partner 
- Dealing with children 
Emotional problems 
-Worry 
- Sadness 
- Depression 
- Nervousness 
Spiritual/religious concerns 
- Relating to God 
- Loss of faith 
- Other problems 
Physical problems 
-Pain 
-'Nau'sea 
- Fatigue 
-Sleep 
- Getting around 
- Bathing/dressing 
- Breathing 
- Mouth sores 
-Eating 
-Indigestion 
- Constipation/diarrhea 
- Bowel changes 
- Changes in urination 
- Fevers 
- Skin dry/itchy 
- Nose dry/congested 
- Tingling in hands/feet 
- Feeling swollen 
, - Se:<ual 
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Appendix B 
Rotterdam Symptom Inventory 
In this questionnaire you will be ask about your symptoms. Would you please, for all symptoms 
mentioned, indicate to what extent you have been bothered by it, by circling the answer most 
applicable to you. 71he questions are related to the past week. 
Example: Have you been bothered, during the past week, by 
headaches not at all a little quite a bit very much 
Have you, during the past week, been bothered by 
lack of appetite not at all a little quite a bit very much 
irritability not at all a little quite a bit very much 
tiredness not at all a little quite a bit very much 
worrying not at all a little quite a bit very much 
sore muscles not at all a little quite a bit very much 
depressed mood not at all a little quite a bit very much 
lack of energy not at all a little quite a bit very much 
low back pain not at all a little quite a bit very much 
nervousness not at all a little quite a bit very much 
nausea not at all a little quite a bit very much 
despairing about the future not at all a little quite a bit very much 
difficulty sleeping not at all a little quite a bit very much 
headaches not at all a little quite a bit very much 
vomiting not at all a little quite a bit very much 
dizziness not at all a little quite a bit very much 
decreased sexual interest not at all a little quite a bit very much 
tension not at all a little quite a bit very much 
abdominal (stomach) aches not at all a little quite a bit very much 
anxiety not at all a little quite a bit very much 
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constipation 
diarrhea 
acid indigestion 
shivering 
tingling in hands or feet 
Ie 
difficulty concentrating 
not at all 
not at all 
not at all 
not at all 
not at all 
not at all 
sore mouth/pain when swallowing not at all 
loss of hair not at all 
burning/sore eyes not at all 
shortness of breath not at all 
dry mouth not at all 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
a little quite a bit 
A number of activities is listed below. We do not want to know whether you 
actually do these, but only whether you are able to perform them presently. 
Would you please mark the answer that applies most to your condition of the 
past week. 
very much 
very much 
very much 
very much 
very much 
very much 
very much 
very much 
very much 
very much 
very much 
unable only with 
help 
without help, 
with difficulty 
without help 
care for myself o o o o 
walk around the house o o o o 
light housework/household jobs o o o o 
climb stairs o o o o 
heavy housework/household jobs o o o o 
walk out of doors o o o o 
go shopping o o o o 
go to work 0 0 0 0 
All things considered, how would you 0 excellent 
describe your quality of life during 0 good 
the past week? 0 moderately good 
0 neither good nor bad 
0 rather poor 
0 poor 
0 extremely poor 
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Would you please check whether you answered all the questions? 
Thank you for your help patient number _____ _ 
From: deHaes et aI., 1996, Appendix 2 
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Appendix C 
Manitoba Cancer Treatment & Research Foundation 
Functional Living Index: Cancer (FUC) 
1. Most people experience some feelings of depression at times. Rate how often you feel these 
feelings. 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Never Continually 
2. How well are you coping with your everyday stress? 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Not well Very well 
3. How much time do you spend thinking about your illness? 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Constantly Never 
4. Rate your ability to maintain your usual recreation or leisure activities 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Able Unable 
5. Has nausea affected your daily function? 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Not at all A great deal 
6. How well do you feel today? 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Extremely 
Poor 
7. Do you feel well enough to make a meal or do a minor household repair today? 
Extremely 
well 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Very Not 
Able Able 
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8. Rate the degree to which your cancer has imposed a hardship on those closest to you in the past 
two weeks. 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
No 
Hardship 
9. Rate how often you feel discouraged about your life. 
Tremendous 
Hardship 
1---------------Ii;---I------------------I--------------------I------------------1---------------------1-------------------I 
1 2 3 4 5 6 7 
Always Never 
10. Rate your satisfaction with your work and your jobs around the house in the past month. 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
~~ ~~ 
Dissatisfied Satisfied 
11. How uncomfortable do you feel today? 
1-------------------1------------------1--------------------1------------------1--------7------------1-------------------1 
1 2 3 4 5 6 7 
Not at all Ve~ 
Uncomfortable 
12. Rate in your opinion, how disruptive your cancer has been to those closest to you in the past two 
weeks. 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Totally No 
Disruptive Disruption 
13. How much is pain or discomfort interfering with your daily activities? 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Not at all A great deal 
14. Rate the degree to which your cancer has imposed a hardship on you (personally) in the past two 
weeks. 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Tremendous No 
Hardship Hardship 
15. How much of your usual household tasks are you able to complete? 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
All None 
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16. Rate how willing you were to see and spend time with those closest to you, in the past two weeks. 
1-------------------1------------------1--------------------1------------------1---------------------1-------------------1 
1 2 3 4 5 6 7 
Unwilling 
Manitoba Cancer Treatment & Research Foundation, 1993 
Very 
Willing 
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Appendix D 
Brief Symptom Inventory 
Sample questions 
Instructions: Below is a list of problems people sometimes have. Please read each one carefully 
and blacken the circle that best describes HOW MUCH THAT PROBLEM HAS DISTRESSED 
OR BOTHERED YOU DURING THE PAST 7 DAYS INCLUDING TODAY. 
Not A Moderately Quite Extremely 
At little a 
All bit bit 
l. 0 1 2 3 4 Nervousness or shakiness inside 
2. 0 1 2 3 4 Faintness or dizziness 
3. 0 1 2 3 4 The idea that someone else can control your 
thoughts 
4. 0 1 2 3 4 Feeling that others are to blame for most of your 
trouble 
5. 0 1 2 3 4 Trouble remembering things 
6. 0 1 2 3 4 Feeling easily annoyed or irritated 
7. 0 1 2 3 4 Feeling afraid in open spaces or on the streets 
8. 0 1 2 3 4 Pains in the head or chest 
9. 0 1 2 3 4 Feeling that most people cannot be trusted 
From: Leonard R. Derogatis, 1993 
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Appendix E 
Symptom Distress Scale 
Sample questions 
How much pain you are feeling? 
Worst pain)" 
Have ever had--------------------------------------------------No pain 
How much nausea are you experiencing? 
I feel as sick 
as I possibly I do not feel 
could be-------------------------------------------------------sick at all 
How is your appetite? 
I cannot face My appetite is 
food at all---------------------------------------------------normal for me 
How do you sleep? 
Could not be Sleep as well 
worse--------------------------------------------------------as ever 
From: R. McCorkle and Young, 1978, p. 112 
Fatigue 
Frequency 
Distress 
Adapted Symptom Distress Scale-2 (ASDS-2) 
a 
I feel.tired. 
I feel good 
about the 
amount of rest 
Sample Question 
1 2 3 
I am occasionally I am frequently I am tired 
a little tired tired most of 
the time 
When I am tired, When I am Whenl am 
it causes me tired, it causes tired, it 
slight distress me moderate causes me 
distress great distress 
From: V. A., Rhodes, 2000, p. 51 
4 
I am very tired all 
of the time 
When I an tired, 
it causes me 
distress as 
severe as it 
can be 
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During the past 
Appendix F 
Memorial Symptom Assessment Scale 
Sample Questions 
week did you have I$' If yes, how severe 
any of the 
no 
If Yes, how often did you have it? was it? 
following 
symptoms? 
A B C Dt E F G 
Vomiting 1 2 3 4 1 2 3 
Worrying 1 2 3 4 1 2 3 
Frequency: A = rare; B = occaslOnal; C = frequent; D = almost constant 
Severity: E = slight; F = moderate; G = severe; H = very severe 
Distress: I = not at all; J = a little bit; K = quite a bit; L = very much 
From: R.K. Portenoy et aI., 1994, p. 1330. 
H 
4 
4 
If yes, how much 
did it distress or 
bother you? 
I J K L 
1 2 3 4 
1 2 3 4 
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Appendix G 
Edmonton Symptom Assessment Scale 
Sample Questions 
On a scale of 1 to 10, with 1 being not bothered and 10 being severely bothered,how much have 
the following sY111ptoms bothered you in the last hours? 
1. Pain 
2. Activity 
3. Nausea 
4. Depression 
5. Anxiety 
6. Drowsiness 
7. Appetite 
8. Wellbeing 
9. Shortness of breath 
From: Edmonton Palliative Care; http://www.palliative.org/ca-essasdownload.html 
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Appendix H 
Instruction Sheet 
1. Please complete the demographic sheet. Remember that all information that 
you supply is confidential. If the item does not apply to you just mark it with N/ A 
,k 
for not applicable. 
2. There are four short tests included in your packet. Many of the same questions 
will be asked on different tests. Please answer then on each test. 
a. The first test is the Distress Thermometer. Please mark how distressed 
you have been over the past week by drawing a line on the thermometer that 
most closely represents the amount of distress. Then check the causes of 
your distress on the lists. 
b. The second test is the Brief Symptom Inventory. Do not complete any 
identifying information. Please read the instructions, look at the example 
and answer all questions. 
c. The third test is the Rotterdam Symptom Checklist. Please read the brief 
instructions, look at the example and answer all questions. 
d. The fourth test is The Functional Living Index Cancer. Please read each 
question and mark the place on the line that best describes your response to 
the question. 
3. When you have completed the demographic sheet and all of the tests place all 
of the sheets into the envelope that was given to you. Seal the envelope and return 
it to the nurse. Thank you. 
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Appendix I 
Demographic Sheet 
Please check the boxes on both sides of the page that best describe you. 
Male 
Female 
Inpatient 
Outpatient 
Age 
18 - 30 
31 - 43 
44 - 55 
56-67 
68 - 79 
79 - 91 
Type of Cancer 
Colon/Rectal 
Breast 
Ovarian 
Prostate 
Stomach 
Lymphoma 
Hodgkin's 
Lung 
Stage of Cancer 
Primary Occurrence_ 
Reoccurrence 
Local 
Metastatic 
Length of Time Since this Diagnosis 
3 months or less 
3 months to 1 year __ _ 
More than 1 year __ _ 
Highest Level of Education 
Some High School 
High School Diploma 
Some College 
College Degree 
Graduate Degree 
Trade/Teclmical School 
Living Arrangements 
Live Alone 
Live with spouse/S.O. 
Live with spouse/S.O 
and dependent children 
Live with parents 
Live with spouse and 
parents 
Other 
Annual Household Income 
Less than $10,00o __ 
$10,001 - $25,000 
$25,001 - $50,000 
$50,001 - $75,000 
$75,001 -$120,00o __ 
More than $120,001 
(Over) 
Current Treatment 
Surgery 
Chemotherapy 
Radiation 
Hormone 
Current Medications 
Pain 
Nausea 
Fatigue 
Vitamins 
Hormones 
Other 
Current Level of Pain 
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Ethnicity 
Caucasian 
African-American 
Hispanic 
Other 
Current Employment 
40 hours a week or more 
21 - 39 hours a week 
20 hours a week or less 
Unemployed by choice 
Disabled 
0 _____ 1 ____ ~2 _____ 3 _____ 4 _____ 5 _____ 6 _____ 7 8 9 10 
----- -----
no 
pam 
worst 
possible 
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Appendix J 
Consent to Participate in Research on a New Measurement of Distress Experienced by People 
with Cancer 
Principal Investigator 
Carole J Moretz MA., MSN 
Psychology Intern 
(610) 402-0551 
PURPOSE: You are being asked to participate in a research study. The purpose of the study is 
to complete four questionnaires in order to find out if the new "Distress Thermometer" can 
measure cancer patients' distress. It will take about thirty minutes to fill out the questionnaires. 
INVESTIGATORS: 
Principal Investigator 
Name: Carole J. Moretz MA, MSN 
Department: Intern, Cancer Support Team 
John and Dorothy Morgan Cancer Center 
Address: Lehigh Valley Hospital 
Cedar Crest & 1-78 
Allentown, Pennsylvania 18105-1556 
Phone: (610) 402-0551 
Responsible Investigator 
Name: 
Department: 
Address: 
Phone: 
Stephanie Felgoise Ph.D 
Licensed Clinical Psychologist 
Assistant Director of Research 
Philadelphia College of Osteopathic Medicine 
4190 City Avenue 
Philadelphia, Pennsylvania 19131-1693 
(215) 871-6543 
RISKS: You will be asked to write the answers to many questions. It takes about thirty minutes 
to fill out all of the testing materials. Reading and answering these materials may be tiring. The 
questions may be asked many times and may be upsetting to some people. You may realize that 
you have a problem that you did not know about or were able to ignore before. If this happens 
you might worry about the problem or become upset. If you get upset, tell your nurse or call 
(610) 402-CARE for information about how to get help. 
BENEFITS: You may not benefit directly from this research. The research may benefit other 
cancer patients in the future by helping hospital staff to identify cancer patients who need help 
to solve problems that cause them to be upset. 
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COMPENSATION FOR INJURY OR ILLNESS: You understand that in the event of physical 
or psychological injury, treatment will be provided by Lehigh Valley Hospital. The costs of 
treatment will be charged to you or your insurance company. Lehigh Valley Hospital will not 
be responsible for providing either financial compensation or free medical treatment. 
CONFIDENTIALITY STATEMENT: Any information about you or your treatment obtained 
from this research-in~luding your medical history, personal data, and written test results-will 
be kept confidential and never identified in any report. Should results of this study be reported 
in medical or psychological journals or at meetings, the names of all participants will remain 
anonymous. Only authorized representatives, Carole Moretz the principle investigator, Dr. 
Stephanie Felgoise her supervisor, and members of the research committee will have access to 
the records relating to this research. All information examined will be coded and kept 
confidential. 
OPTION OF WITHDRAWAL WITHOUT PREDJUDICE: You can decide not to participate in 
this study or can drop out at any time. Your health care will not be affected if you decide not to 
be in the study, or if you decide to drop out. Your participation is entirely voluntary. If you 
want to be in the study, we are required by federal regulations (45CFR 46) to have you read the 
following paragraph and sign your name below it. 
I have been given the opportunity to ask questions, and all of my questions have been 
answered. I consent to participate in this study. I understand that ifI have further questions 
about this study I may contact Carole Moretz by telephoning (610) 402-0551, her supervisor Dr. 
Stephanie F elogise at (215) 871-6543 or want information regarding my rights as a research 
subject, I may contact Thomas Wasser, Ph.D, Institutional Review Board Administrator at 
Lehigh Valley Hospital by telephoning (610) 402-2525 
Patient Signature (or Patient's Representative) Date 
Investigator Signature Date 
Witness Signature Date 
